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Abstract
Introduction: Breast cancer recurrence continues to be a significant challenge in the clinic.
Despite successful removal and/or treatment of the original tumour, many patients
experience relapse in the breast or at distant sites. Furthermore, the diagnosis of metastatic
disease often occurs too late for effective treatment. Methods: In this thesis, we combine
iron-based cellular MRI and longitudinal BLI to noninvasively track the fate of breast
cancer cells into overt tumours in the mouse brain. We then apply this imaging model to
study the effect of a primary breast tumour on the growth of secondary metastases in an
immune competent mouse model. Finally, we utilized dual-luciferase BLI to investigate
the potential of self-homing circulating tumour cells (CTCs) as a novel cancer theranostic
in both orthotopic and metastatic models of breast cancer. Results: BLI complemented our
cellular MRI technologies well by providing longitudinal measures of cancer cell viability.
Using in vivo BLI/MRI, we demonstrated the presence of a 4T1 primary tumour
significantly enhances total brain tumour burden. Finally, using dual-luciferase BLI, we
demonstrated the ability of experimental CTCs to home to and treat primary tumours and
disseminated breast cancer lesions. Conclusion: MRI and BLI are complementary
technologies to noninvasively study the fate of breast cancer cells, as well as the
mechanisms contributing to metastasis including CTR/CTE and tumour self-homing.
Furthermore, we provide evidence that CTCs are a novel theranostic platform for the
visualization and treatment of pre-established tumour sites throughout the body.
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Summary for Lay Audience
Introduction: Metastasis is defined as the spread of cancer cells from the original tumour
to other parts of the body and is responsible for the majority of cancer related deaths. Thus,
there is a need to better understand the mechanisms that contribute to the progression and
spread of cancer. Methods: In this thesis, we used novel molecular imaging tools to study
potential mechanisms of breast cancer metastasis in mouse models. We combined two
complementary imaging technologies, cellular magnetic resonance imaging (MRI) and
bioluminescence imaging (BLI) to get a more complete picture of breast cancer cell fate in
the brain over time. We then applied these technologies to study the impact of a primary
tumour on the growth of secondary metastases in the body. Finally, we applied noninvasive imaging to investigate the potential of circulating tumour cells as a novel delivery
vehicle for anti-cancer therapeutics in mouse models of breast cancer. Results: BLI
complemented our cellular MRI technologies well by providing longitudinal measures of
cancer cell viability. Using in vivo BLI/MRI, we demonstrated the presence of a primary
tumour enhances total brain tumour burden. Finally, using BLI, we demonstrated the
ability of circulating tumour cells to home to and treat primary tumours and disseminated
lesions. Conclusion: MRI and BLI are complementary technologies to noninvasively study
the fate of breast cancer cells, as well as the mechanisms contributing to metastatic spread.
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Chapter 1
1

Introduction

This thesis employs cellular magnetic resonance imaging (MRI) and bioluminescence
imaging (BLI) to visualize metastatic disease in animal models of breast cancer, to
investigate potential mechanisms that contribute to metastatic spread, and to evaluate the
ability of circulating tumor cells to home to pre-established lesions. This introductory
chapter discusses how metastasis occurs, the relevant mechanisms we are exploring, and
the imaging technologies we are using. This chapter provides background information and
motivation for the studies presented in this thesis.

1.1

Motivation and Overview

Breast cancer recurrence continues to be a significant challenge in the clinic. Despite
successful removal and/or treatment of the original tumour, many patients experience
relapse in the breast or at distant sites. Furthermore, the diagnosis of metastatic disease
often occurs too late for effective treatment as a result of clinical imaging modalities that
lack the sensitivity necessary for early detection.

In this thesis, experimental imaging technologies are applied to study the mechanisms that
contribute to breast cancer metastasis. In Chapter 2, we explore the advantages of
combining iron-based cellular MRI and longitudinal BLI to noninvasively track the fate of
solitary cancer cells into overt tumours in the mouse brain. In chapter 3, we apply this new
imaging model to study the effect of a primary breast tumour on the growth of secondary
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metastases in an immune competent mouse model. In chapter 4, we utilize dual-luciferase
BLI to visualize the tumour self-homing capabilities of experimental circulating tumour
cells (CTCs) in both orthotopic and metastatic models of breast cancer. Further, based on
our self-homing results, we engineered CTCs with a suicide gene therapy system to explore
their potential as a delivery vehicle for anti-cancer drugs. Finally, chapter 5 summarizes
the major findings and significance of this thesis. In addition, limitations of this work and
future directions are discussed.

1.2

Metastatic Breast Cancer

Breast cancer is the second leading cause of cancer related mortality in North America with
a 99% 5-year survival rate for localized disease (stage I) that drops to 85% for regional
disease (stages II-III), and further drops to a dismal 26% when the disease is metastatic
(stage IV) at the time of diagnosis [1]. Breast cancer metastasis occurs when cells leave the
original breast tumour, travel through the circulation and spread to other organs, most
commonly the brain, bone, lung and liver [2].

Clinically, breast cancer can be divided into three main subtypes: 1) those expressing the
estrogen receptor alpha (ER+), which typically also express the progesterone receptor
(PR+), 2) those that overexpress human epidermal growth factor receptor 2 (HER2+) and
3) those that do not express any of the three markers termed “triple negative” breast cancers
(TNBC) [3-6]. More recently, five additional molecular subtypes of breast cancer have
been identified as a result of advancements in gene expression profiling. These include 1)
luminal A (ER+, with low proliferation signatures), 2) luminal B (ER+, with high
proliferation signatures), 3) basal like, 4) HER2+ enriched, and 5) normal breast-like.
2

Additionally, the Claudin-low subtype was identified and characterized as having low
expression of Claudins 3, 4 and 7 [7], enriched for mesenchymal markers [8], and often a
triple-negative phenotype. Each subtype has been shown to have different clinical features
including common sites of metastasis, treatment response and overall survival [9-10].

1.2.1 Brain Metastasis
Breast cancer is the second most likely cancer to metastasize to the brain, estimated to be
present in 0.41% of all breast cancer patients at the time of diagnosis [11-12]. Brain
metastases can occur in all breast cancer patients; however, patients with triple negative
and HER2+ breast cancer have a significantly higher incidence of brain metastasis than
other breast cancer subtypes. A study by Jin and colleagues found that approximately one
third of patients with TNBC and HER2+ breast cancer will develop brain metastases
throughout the course of their disease [13]. Other studies have reported brain metastasis
incidence rates of up to 50% for HER2+ breast cancer patients [14]. Furthermore, TNBC
patients have a worse prognosis after developing brain metastases, with a shorter median
survival time than in patients with other subtypes of breast cancer including HER2+ [13].
In this thesis, we utilize mouse models of TNBC and HER2+ breast cancers that
metastasize to the brain.

1.2.2 Metastatic Colonization
Cancer metastasis has been shown to be a very inefficient process with the primary tumour
shedding a high number of CTCs and very few going on to form overt metastases [15].
Experimental studies have shown that approximately 0.01% of cells injected into the

3

circulation will develop into metastases, with the majority of cells being destroyed by either
the immune system or hemodynamic forces [16]. For metastatic cancer cells to successfully
colonize the brain, they must survive within the vasculature, arrest in the microcirculation,
and extravasate into the brain parenchyma. While many cancer cells will successfully
execute these initial steps to get into the brain, survival outside the vasculature and
adaptation to the surrounding tissue are both extremely inefficient steps, as they require
sufficient oxygen and nutrients prior to any new tumour vasculature being formed [17-18].

1.2.3 Dormancy
Cancer cells that successfully colonize distant organs have three potential cell fates: 1)
proliferation to form metastases, 2) cell death or 3) cell dormancy. Cancer cell dormancy
is when a cancer cell goes into a quiescent state, remaining viable but not actively
proliferating. A cancer cell can remain in a dormant state until it is triggered to become
proliferative again. The factors that influence a cancer cell’s ability to escape dormancy
remain fairly unclear but are likely to contribute to cancer recurrence [19-21].

Importantly, there are currently no definitive markers to identify dormant cancer cells in
vivo, which makes the study of cancer cell dormancy very challenging. Previous work has
included ex vivo studies that confirm the absence of both proliferative and apoptotic
markers to suggest a state of dormancy, as well as the retention of imaging agents to exploit
nondividing from dividing cell populations in vivo [22]. In 2002, Naumov and colleagues
showed that breast cancer cells can be labeled with fluorescent nanospheres and imaged
with intravital microscopy. They defined dormant cells as those that retain their fluorescent
label over time in vivo, as proliferative cells lose their label through cell division and
4

become undetectable. They found a large proportion of cells persisted as dormant cancer
cells and were able to confirm viability by recovering the tissue and showing these cells
were capable of returning to a proliferative state both in culture and in vivo. Similarly,
groups including ours have shown the retention of iron oxides can be used to longitudinally
visualize nonproliferative cancer cells with cellular MRI technologies. This technique is
further discussed in the subsection “Cellular MRI” [23-25].

1.2.4 Breast Cancer Recurrence
In many cases, women presenting with only detectable primary tumours, and whose initial
treatment was deemed successful, can relapse many years following initial treatment [26].
In a study by Dent et al., it was found that patients with TNBC had a significantly increased
likelihood of cancer recurrence compared to those with other subtypes. However, the time
of recurrence is also different between subtypes, with TNBC patients having an increased
risk of recurrence at 1 to 3 years following diagnosis, that drops after 3 years, and patients
with other subtypes having a fairly steady risk of recurrence throughout the entire follow
up period [27]. In addition to dormancy reawakening, this may be a consequence of
increased intra-tumoural heterogeneity in TNBC. Previous work has shown that primary
TNBC can be very clonally diverse among patients with the same stage of cancer and that
distinct sub-clones may be capable of maintaining homeostatic balance between clonal
populations and thus, enhancing tumour growth [28]. However, intra-tumoural
heterogeneity is not commonly considered in clinical practice. Patients are typically treated
based on the hormone receptor status of their primary tumour, and metastatic sites
(especially the brain) are not always biopsied for biomarker testing. As a result, cancer
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recurrence may be attributed to treatment resistance of tumours that no longer carry the
biomarkers/mutations that were present in the original tumour as well as the presence of
dormant cells that are not effectively treated with common chemotherapeutic drugs that
target proliferating cells [29]. This calls for a better understanding of cancer cell dormancy,
the mechanisms of metastasis, and proactive treatments targeted at eliminating both
dormant cancer cells and genetically diverse metastases.

1.2.5 Treatment of breast cancer
Most breast cancer patients will receive some form of surgery throughout the course of
their disease. Surgical intervention is performed for a number of reasons including
removing cancerous tissue (breast conserving surgery or mastectomy), investigative
purposes (lymph node biopsy), breast reconstruction surgery, or to relieve symptoms
associated with advanced cancer [30]. Often after breast conserving surgery or
mastectomy, radiation therapy will be performed to lower the chance of the cancer
returning in the breast and/or at distant sites. Alternatively, radiation therapy may be used
to treat metastases in other parts of the body such as the bone or brain [31-32]. For those
with hormone receptor positive breast cancers (ER- or PR- positive), hormone therapy is
typically recommended as a way to systemically treat cancer cells throughout the body.
For these cancers, high estrogen levels help the cancer cells grow and thus, most therapies
work by lowering or preventing estrogen from acting on cancer cells. Many breast cancer
patients may also receive some form of chemotherapy (i.e., doxorubicin, cisplatin,
paclitaxel) throughout the course of their disease. Neoadjuvant chemotherapy is often used
to try to shrink a tumour prior to surgery while adjuvant chemotherapy can be used to kill
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off any remaining cells that may have been left behind during surgery or to lower the risk
of cancer recurrence [33].

1.2.6 Treatment of brain metastasis
While many of the above treatment options have shown to be effective in treating breast
tumours, current therapies often fail at a time when metastatic disease is already present
[34-35]. Treatment of breast cancer brain metastases typically involves a combination of
surgery with radio- and/or chemotherapy. Treatment plans often depend on the number of
metastases within the brain, whereby patients having multiple lesions typically receive
whole brain radiotherapy treatment (WBRT), while surgery and stereotactic radiosurgery
(SRS) are feasible options for patients with 1-3 metastases and an otherwise good
prognosis. In WBRT, high energy beams are applied to the entire brain in efforts to kill
multiple metastases throughout. However, in doing so, there is the potential to damage
healthy, non-cancerous tissue and WBRT is associated with cognitive impairment [31-32].
Alternatively, SRS can deliver precise and targeted radiation in fewer, high dose
treatments, sparing healthy surrounding tissue [36].

Chemotherapy is often used in addition to WBRT, surgery or SRS to further decrease the
chances of cancer recurrence. However, chemotherapy also presents some challenges in
treating brain metastases. This is due to the highly selective barrier that surrounds the
capillaries within the brain, known as the blood brain barrier (BBB), that allows entry of
small molecules (hormones, nutrients etc.) but restricts entry of larger molecules such as
toxins or bacteria. As a result, the BBB is typically very good at preventing most
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chemotherapeutics from getting into the brain at an effective dose [29, 37]. Previous studies
have shown that brain metastasis from breast cancer involves mediators such as
cyclooxygenase (COX-2) and epidermal growth factor receptor (EGFR) to enhance
extravasation through non-fenestrated capillaries [38]. When a cancer cell extravasates into
the brain, the protective cells that make up the surrounding vasculature are compromised,
and the BBB becomes known as the blood-tumour barrier (BTB). While the BBB in a
healthy brain prevents many therapeutics and contrast agents from diffusing out of the
circulation, the BBB/BTB can be disrupted (naturally or drug induced) in metastases
resulting in “leaky” tumours that have enhanced permeability [39]. As a result, imaging
agents such as gadolinium chelates that do not typically cross the BBB in a healthy brain,
have been adapted in the clinic to effectively image permeable tumours with magnetic
resonance imaging (MRI). This technique is further discussed in the subsection “MRI of
cancer”. Unfortunately, relying on BBB/BTB permeability for drug delivery has not been
as successful, with common breast cancer drugs such as doxorubicin and trastuzumab
showing effective treatment of extracranial metastases but not brain metastases [29, 38]. In
recent years, there has been some development in small molecule therapies including
capecitabine and lapatinib however, drug uptake has shown to be extremely variable [40].

1.3

Mechanisms of metastasis

Since metastasis is responsible for the majority of cancer related deaths, research has been
focused on gaining a better understanding of the underlying mechanisms that regulate
cancer metastasis in breast cancer as well as other cancer types. One group of potential
mechanisms studied have suggested a relationship between the primary breast tumour and

8

the growth of secondary tumours in the body [41-67]. This thesis is focused on two of these
concepts: concomitant tumour resistance (CTR) whereby the primary tumour restricts the
growth of secondary tumours; and concomitant tumour enhancement (CTE) whereby the
primary tumour stimulates secondary tumour growth (Figure 1.1).
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Figure 1.1 Schematic of concomitant tumour resistance vs. concomitant tumour
enhancement: CTR occurs when an existing tumour inhibits the growth of secondary
tumours throughout the body. As a result, surgical resection of the primary tumour
can lead to an abrupt acceleration of distant metastases. Conversely, CTE occurs
when an existing primary tumour accelerates the growth of secondary tumours such
that surgical resection can lead to regression of metastases.
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1.3.1 Concomitant tumour resistance
The phenomenon of concomitant tumour resistance (CTR) occurs when a host bearing a
primary tumour inhibits the growth of secondary tumours throughout the body. The clinical
relevance of CTR has been observed in patients where the removal of a primary tumour is
followed by an abrupt acceleration of residual metastatic disease, suggesting the primary
tumour mitigates the continued growth of secondary tumours [41-45]. For example, El
Saghir and colleagues reported a case of non-small cell lung cancer whereby the patient, a
43-year old male, had tumour recurrence and accelerated growth following a minor trauma
to the skull bone. The authors suggest the unusual growth may be a result of dormant cancer
cells that were triggered by a new environment of stimulating factors following injury [45].

A number of hypotheses have been proposed to explain the CTR phenomenon. The first
was by Ehrlich and Tyzzer in 1905 who proposed the “athrepsia theory”, whereby nutrients
that are necessary for secondary tumour growth are consumed by the primary tumour,
restricting metastatic progression prior to resection [46]. They first observed this
phenomenon in a rat sarcoma model, where the growth of one tumour was able to inhibit
the growth of a subsequently injected tumour in the same animal. This theory was later
supported by Marie and Clunet, who found a dramatic increase in the frequency of distant
visceral metastases when a primary tumour was partially resected in mice in comparison
to the number of spontaneous lesions that occur from an intact primary tumour [47]. In
1913, Tyzzer similarly found that Japanese waltzing mouse tumours that were partially
excised led to larger metastases compared to control mice not undergoing tumour resection
[48]. This study was considered further support for the athrepsia hypothesis.
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The immunological hypothesis, coined “concomitant immunity” was originally proposed
by Bashford et al., suggesting the growth of a tumour generates an anti-tumour immune
response that is capable of preventing the growth of small secondary metastases [49]. This
explanation has been supported by numerous preclinical studies using chemically or virally
induced immunogenic murine tumour models [50-51]. For example, Franco and colleagues
demonstrated in mouse models of bone and breast cancer that there may be two separate
peaks of concomitant resistance that occur throughout tumour development. The first peak
is caused only by small immunogenic tumours and is associated with a T-cell dependent
immune reaction, while the second peak was found to be independent of tumour
immunogenicity and caused by the presence of a serum factor in tumour bearing animals
[51]. Similarly, Kirstein et al., demonstrated the ability to inhibit the growth of
experimental lung metastases through reduction of circulating platelets and tumour
associated thrombi in a mouse model of melanoma. Additionally, they restored platelet
numbers and were able to re-establish tumour associated thrombus formation and
experimental metastasis [52].

In addition, others have suggested the primary tumour can produce anti-proliferative and/or
anti-angiogenic molecules into the circulation that indirectly limit the growth of secondary
implants [53-57]. For example, O’Reilly et al, have shown that the systemic administration
of angiostatin is capable of efficiently blocking neovascularization and thus, the growth of
lung metastases in mouse models of cancer [56]. Ruggerio and colleagues also reported
that serum from tumour bearing mice exhibited anti-proliferative properties that were
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proportional to the size of the primary tumour as well as the relative amount of concomitant
resistance observed [57]. The serum factors responsible for inhibition of secondary tumour
growth were later identified as meta- and ortho-tyrosine (M- and O-tyrosine), two
uncommon tyrosine isomers [58]. Mechanistic studies have since related the anti-tumour
effects produced by these tyrosine isomers with inhibition of mitogen-activated
protein/extracellular signal-regulated kinase pathway as well as inactivation of STAT3,
which may induce a state of cancer cell dormancy [59].

1.3.2 Concomitant tumour enhancement
In addition to CTR, concomitant tumour enhancement (CTE) also exists, whereby the
presence of a primary tumour stimulates the growth of secondary tumours [60-62]. This
was first observed by Ando and colleagues in studying a mouse model of fibrosarcoma.
They found that animals with a growing subcutaneous tumour in the hindlimb developed
significantly more lung metastases after secondary inoculation of intravenously injected
cancer cells compared to control animals. Interestingly, they found that the growth of an
intramuscular tumour at a distant site within the same animals could be prevented by the
growth of an existing primary tumour [60]. This is the first reported case of CTR and CTE
co-existing in the same animals. Similarly, Janik et al, found a tumour bearing host is first
protected and then made more susceptible to the development of metastases. They showed
that the number of experimental metastases in the lungs was highest in animals bearing the
oldest primary tumour (day 28), however, a moderately sized tumour (day 16) caused fewer
metastases than control mice without a primary tumour suggesting an initial inhibitory
CTR effect [61].
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Other groups have suggested it is the ratio between the size of the primary and the
secondary implant that determines whether CTR or CTE occurs. Bruzzo et al.,
demonstrated that a high ratio between the mass of the primary tumour relative to the mass
of the secondary tumour can lead to CTR, while a low ratio can lead to a CTE effect [62].
More recently, McAllister and colleagues showed that osteopontin that is released into the
circulation by the primary tumour is capable of promoting the growth of otherwise poorly
growing implants. They demonstrated an activation of stromal cell precursors caused by
osteopontin, consequently making it easier for cancer cells to recruit them and initiate
growth [63]. Additionally, a few clinical cases of CTE have been reported whereby a
nephrectomy for renal cell carcinoma is followed by a suspected regression of hepatic
and/or pulmonary metastases [64-67].

Despite the relevance of CTR and CTE, clinical evidence of each remains lacking due to
the fact that investigation depends on the presence of a growing primary tumour which
often does not coincide with clinical treatment plans. Many groups have studied CTR and
CTE in various experimental animal models; however, most of these studies have evaluated
metastatic lesion growth using endpoint histology. Parts of this thesis focus on the
development and application of longitudinal molecular imaging tools to noninvasively
study CTR and CTE in mouse models of breast cancer metastasis.
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1.3.3 Tumour self-seeding and/or self-homing
As described above, in the traditional theory of metastasis, cancer cells can leave the
original tumour and unidirectionally seed metastases in nodes and/or distant sites.
However, in 2006, Norton and Massague suggested CTCs that are shed from the primary
tumour may also return to, and grow in, the tumour of origin and other established lesions.
This fairly new idea of multidirectional metastasis was termed tumour “self-seeding” or
“self-homing” and has since been shown to occur in animal models of human breast, colon
and melanoma cancer [68-69].

15

Figure 1.2 Schematic of tumour self-homing: Tumour self-homing or self-seeding
occurs when cancer cells are shed from an established tumour (primary or distant
metastases) and travel through the circulation to return to and grow at the original
tumour site.
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The concept of tumour self-homing has been shown to involve both the recruitment
capabilities of the original tumour as well as the migratory or “seeding” potential of the
CTCs themselves. Firstly, Carmaliet and Jain have shown that the leaky vasculature
associated with an established tumour may permit the seeding and survival of cancer cells
more easily than at a new site [70]. While one of the rate-limiting steps of unidirectional
metastasis is adaptation to distant organs, CTCs may not need further adaptation to initiate
growth in the microenvironment of their source tumour. This hypothesis was further
supported by work from Kim and colleagues showing that tumours can become efficiently
seeded by CTCs derived from a secondary tumour implant, distant metastases, or systemic
injection, suggesting the primary tumour has the ability to recruit CTCs. They further
attributed these findings to the cytokines, IL-6 and IL-8, that are produced by the primary
tumour and act as chemoattractants to efficiently recruit CTCs [69]. More recently, Vilalta
and colleagues have shown that radiation of tumour cells produces granulocytemacrophage colony stimulating factor (GM-CSF) that can also act to enhance the
recruitment of CTCs to irradiated sites. They provide evidence suggesting radiation
induced cancer self-homing may act as a potential mechanism for cancer recurrence and,
similar to studies by Kim et al., they show consistently increased self-homing irrespective
of the route of CTC administration [71].

The characteristics of CTCs that contribute to their ability to self-home have also been
studied. Kim et al., found that markers such as collagenase-1, fascin-1, and CXCL1 act as
mediators of CTC infiltration into mammary tumours. The expression of these genes in
primary breast tumours has been associated with priming of cancer cells for the seeding of

17

the lungs and brain as well as with relapse in cancer patients. Additionally, they provide
evidence that tumour self-homing selects for a highly aggressive population of CTCs
whereby, metastatic cell populations are more efficient seeders than their respective
parental populations [69].

1.3.4 Development of Self-Homing Cancer Cells as Therapeutic
Vectors
In the last decade, several groups have begun to exploit the self-homing properties of
cancer cells in order to use them as delivery vehicles for anti-cancer therapeutics [72-76].
In 2004, Raykov et al, demonstrated the remarkable ability of metastatic cancer cells to
efficiently deliver oncolytic viruses to pre-established tumours. Using a rat model, they
show hepatoma cells can be successfully employed as H-1 parvovirus carriers to target and
treat lung metastases [72]. Another group similarly showed that the limitations associated
with systemic delivery of oncolytic virus can be overcome by using “carrier” cancer cells
to shield virions from defense mechanisms. Furthermore, they showed that when cancer
cells carrying oncolytic virus are administered systemically, lung tumour burden is
significantly reduced and survival is prolonged compared to naked virion injection [73].

Other groups have engineered self-homing tumour cells to express suicide genes which can
transfer death signals to neighbouring cancer cells in pre-established lesions. Freeman and
colleagues demonstrated this by engineering cancer cells to express the gene for herpes
simplex virus thymidine kinase (HSV-TK). HSV-TK expressing cells are sensitive to
killing by the drug ganciclovir (GCV) and also produce a “bystander effect” whereby
adjacent HSV-TK negative cells can be killed. Freeman et al., showed that survival was
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significantly improved when mice with a pre-existing HSV-TK negative tumour were
injected with secondary HSV-TK positive cells followed by GCV treatment compared to
control animals [74]. Garcia-Castro et al., also showed the value of using suicide gene
therapy in treating metastatic disease. They transduced human breast (MDA-MB-231) or
prostate (PC3) cell lines to express the therapeutic gene cytosine deaminase (CD) that
converts the nontoxic pro-drug, 5 fluorocytosine (5’FC) into an active chemotherapeutic
5-fluorouracil (5’FU). They found that tumour-bearing mice injected with CD expressing
cells and treated with the pro-drug had significantly less primary tumour burden as well as
fewer metastases in both the lungs and kidneys compared to control mice [75]. These
suicide genes offer a unique opportunity to use cancer cells as a therapeutic carrier by
enabling both a safety mechanism of self-induced toxicity as well as an efficacious
bystander effect capable of killing surrounding non-engineered cells.

Dondossola et al., have also shown that cancer cells can be engineered to express
therapeutic genes that influence the tumour microenvironment. In a 2016 study, they
showed that cancer cells can be genetically modified to produce and release tumour
necrosis factor (TNF), a cytokine known to have anti-tumour effects. In mouse models,
they successfully demonstrated that cancer cells engineered to express TNF homed to preestablished tumours, released TNF and consequently damaged the neovascular
endothelium and induced cancer cell death [76].

While the current approaches have shown promise, there are some important limitations of
using cancer cells to carry therapeutic cargo. First and foremost, is the safety aspect of
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introducing new cancer cells into a subject in efforts to treat them. The use of suicide genes
has significantly improved the safety profile of using cancer cells as delivery vehicles
however, further development is needed to enable noninvasive monitoring of their longterm fate in vivo. Likewise, there is a need for imaging tools to determine the self-homing
efficiency of engineered CTCs prior to implementing them as a therapeutic carrier. Parts
of this thesis explore the use of imaging reporter genes to enable noninvasive imaging to
be used to evaluate the self-homing efficiency and therapeutic efficacy of engineered CTCs
in vivo.

1.4

MRI of Cancer

Non-invasive imaging technologies can be used for a number of reasons along the course
of cancer progression. This can include screening and early detection methods (e.g.,
mammography), visualizing the spread and severity of disease, as well as monitoring for
signs of cancer recurrence (active surveillance). Furthermore, imaging technologies play a
pivotal role in cancer treatment including for biopsy needle guidance, surgical/radiotherapy
treatment planning and evaluating responses to most therapies. A number of different
imaging modalities are used both clinically and pre-clinically for imaging cancer, including
optical imaging, ultrasound (US), photoacoustic imaging (PAI), computed tomography
(CT), magnetic resonance imaging (MRI), single photon emission computed tomography
(SPECT), and positron emission tomography (PET). Among these, MRI is one of the most
employed technologies as it provides excellent soft tissue contrast, high resolution images,
and uses non-ionizing radiation [77].
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In the clinic, conventional MRI can be used to assess a variety of tumour characteristics
including tumour size, tumour perfusion, cancer cellularity, tumour metabolism and
tumour pH [78-85]. Among these, contrast enhanced T1-weighted MRI is considered the
most accurate detection method for clinical brain tumours. In preclinical cancer models,
MRI cell tracking can be employed as a way to track specific cell populations in vivo.
Cellular MRI enables longitudinal tracking of both transplanted and endogenous cell
populations depending on the strategy that is used to label cells with contrast agents such
as iron (iron-based cellular MR) or perfluorocarbons (Fluorine-19 MR) [23, 24, 86, 87].
This thesis utilizes iron-based cellular MRI for tracking metastatic breast cancer cells in
the mouse brain.

1.4.1 Basic principles of MRI
In conventional MRI, an image is generated from hydrogen atoms (1H or protons) within
the tissues of our body, predominantly water and fat. A large magnetic field (B0) causes
the protons to align within the body and a radiofrequency (RF) transmitter is applied to
excite protons which results in a change in the orientation of the net magnetization vector.
When the RF pulse is turned off, the protons dephase and relax back to equilibrium,
generating energy that creates detectable MR signal [88]. Since cancerous tissues have
different relaxation rates (T1 and T2) compared to healthy tissues they can generate
different contrast, and therefore, anatomical MRI is a valuable tool to visualize changes in
size, spread and composition of tumours throughout the body [89].
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1.4.2 Generating contrast
In an MR image, the most common forms of contrast weightings are dependent on proton
density (PD), spin-lattice relaxation time (T1), or spin-spin relaxation time (T2). In PDweighted images, regions of hyperintensity represent regions with high numbers of
hydrogen atoms, while T1-weighted contrast is reflective of how long it takes protons to
realign with B0 after an RF pulse is applied. Tissues that have a short T1 such as fat appear
bright in a T1-weighted image, while tissues with a long T1 like water or air appear dark.
Contrast in T2-weighted images depends on the rate of dephasing (spin-spin relaxation) in
a particular voxel following an RF excitation. In T2-weighted images, tissues with a long
T2, like fluids, appear bright, while tissues with a short T2, such as fat, appear dark [88].
Contrast agents can be used to further enhance signal in an area of interest by shortening
the T1 or T2 times of surrounding tissues. Paramagnetic agents such as gadolinium (Gd)
and manganese (Mn) based agents act to shorten T1, resulting in bright or hyperintense
areas in a T1-weighted image, while superparamagnetic agents such as iron-oxides shorten
T2, resulting in signal loss or hypointense regions [88-90]. This thesis involves the use of
iron-oxide nanoparticles.

RF coils are applied to transmit and/or receive the energy necessary to acquire an MR
image. There are two types of coil configurations categorized as either surface or volume
coils, whereby the size, geometry and efficiency of the coil impacts the amount of signal
that can be acquired. While surface coils have shown to have increased sensitivity, the
signal drops off significantly the farther away from the coil one tries to image. In contrast,
volume coils enable a more uniform signal that is independent of depth, making them the
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more common choice for imaging deep tissues such as the brain [91-92]. In this thesis, we
used a custom-built insert gradient as well as a birdcage mouse head RF volume coil to
allow for preclinical imaging on a clinical MR system. This unique MR setup is discussed
further in Chapters 2 and 3.

The two main types of pulse sequences that can be used to generate an MR image are called
spin echo (SE) and gradient echo (GE) sequences. SE imaging typically produces high
quality images; however, can take relatively long to acquire. Alternatively, GE sequences
have shorter TR and take less time to acquire but are susceptible to field inhomogeneities.
In GE sequences, the signal intensity in the image is T2* weighted, which includes signal
loss due to T2 relaxation as well as magnetic field inhomogeneity [88].

In our lab, we have used the balanced steady state free precession (bSSFP) iron-sensitive
MR pulse sequence to detect iron labeled cells (also known as FIESTA, TrueFISP and
balanced FFE) [88]. bSSFP is a type of GE sequence with T2/T1-weighted image contrast.
It is one of the most signal to noise ratio (SNR) efficient sequences as a result of refocusing
the magnetization at the end of each repetition time (TR), generating a “steady state” in
both the transverse and longitudinal planes [88]. Using a bSSFP sequence, iron labeled
cells appear as regions of signal void.

1.4.3 Iron-based Cellular MRI
To increase the conspicuity of cells with MRI, one can label them with iron-oxide
nanoparticles, which are available in different sizes including micron sized iron oxide

23

(MPIO) nanoparticles (diameter  1um), superparamagnetic iron oxides (SPIOs; ~ 50-150
nm in diameter), and ultra-small superparamagnetic iron oxides (USPIOs;  50 nm in
diameter) [93-94]. There are two main techniques to label cells with iron-oxide
nanoparticles. Firstly, cells can be pre-labeled in culture with MPIOs, SPIOs, or USPIOs
prior to transplantation into a subject (Figure 1.3). Many cultured cell types readily take up
these iron oxides by simple coincubation [86,90,95,96] or can be encouraged to internalize
iron particles using transfection agents, electroporation or magnetofection [98-100].
Labelling cells with MPIO offers substantially more iron content per cell and thus,
improves MR detectability to low cell numbers, even single cells [86,90,95,96,101].
Alternatively, SPIOs and USPIOs can also be injected systemically for in vivo or “in situ”
cellular labeling. In this instance, these particles are preferentially taken up by phagocytic
cells of the reticuloendothelial system including macrophages and other immune cell types
[87]. MPIO particles are limited to preclinical studies as their polymer matrix composition
is not biodegradable. Ferumoxytol (Feraheme), a USPIO used for iron replacement therapy
is being investigated for off-label use as an MR contrast agent [102-103].

24

Figure 1.3 Ex vivo iron labeling of cancer cells: Cancer cells can be labeled ex vivo with

iron oxides prior to intracardiac injection into the beating mouse heart. These cells will
travel through the circulation and arrest in distant organs including the brain where
they can be visualized with cellular MRI.
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Iron based cellular MRI has been applied to a number of different disease models to track
different cell types including immune cells, stem cells, pancreatic islets and cancer cells
[23, 24, 87, 97, 105-118]. While in its early years, there were concerns about iron having
an effect on cell function, very few detrimental effects have been observed. However, in
2011, Rohani and colleagues found that MPIO labeled dendritic cells showed differences
in activation and maturation compared to unlabeled cells, though they reported no
difference in cell viability [111]. Importantly, previous work has shown that MPIO and
SPIO labeling of cancer cells does not cause significant changes in cell viability,
proliferation, apoptosis or metastatic efficiency [23, 86, 105].

1.4.4 Cellular MRI of Cancer
Cellular MRI has shown to be an invaluable tool to study the fate of cancer cells in vivo,
enabling noninvasive monitoring of both proliferative and nonproliferative cells [23, 24,
87, 96, 104-105, 114-115]. The main advantage of using iron-based cellular MRI to track
cancer cells in vivo, is that it has high sensitivity. In 2006, Heyn et al., demonstrated for
the first time, that solitary cells can be visualized in the mouse brain using in vivo cellular
MRI. By labelling a macrophage cell line in culture with SPIO, they demonstrated an iron
loading efficiency of approximately 60 picograms of iron per cell and consequently, were
able to visualize single iron-labeled cells in the brain with MRI [105]. Similarly, they
showed this technique was also possible with metastatic breast cancer cells such that,
tracking the fate of individual cancer cells in the brain was feasible. In these studies, MDAMB-231BR cells, a highly brain metastatic variant of human MDA-MB-231 cells, were
loaded with iron, injected into the left ventricle of mice, and monitored with bSSFP-based
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cellular MRI over time. After a month of tumour development, they showed that cells that
had arrested in the brain had three distinct cell fates: 1) signal voids that were present after
injection but disappear for the remainder of the study, deemed “transient”, 2) proliferative
cancer cells that appear as signal voids after injection and later appear as areas of
hyperintensity, representing tumours, and 3) nonproliferative cancer cells that retain their
iron label over time, deemed “dormant”. Furthermore, they confirmed these findings by
co-registering discrete signal voids (representing iron-labeled cells) in MR images with
confocal microscopy images confirming the ability to visualize individual fluorescent cells
with cellular MRI [86].

1.4.5 Limitations of cellular MRI
The application of cellular MRI to study disease has shown tremendous growth in the last
decade. However, there has not been nearly as much work done in tracking cancer cells
compared to other cell populations such as immune, stem or therapeutic cell types [98-100,
106-112, 115-117]. This is likely attributed to the iron label being diluted during rapid
cancer cell division, leading to a limited timeframe for detection of proliferating cancer
cells. Since the iron is stored in the cell body, the amount of iron-oxide will get divided
between daughter cells through each cell division, or lost to the extracellular environment,
until eventually there is no longer enough iron per cell to be detected with MRI. This,
however, can also be beneficial in exploiting non-dividing cell populations, for example,
dormant cancer cells that are not actively dividing and will retain their iron label over time
[23, 24].
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Iron-based cellular MRI also lacks specificity compared to other cell tracking techniques.
While the iron creates a distinct void and optimal contrast in anatomies such as the brain,
there are many naturally dark or hypointense areas throughout the body that are difficult to
distinguish from iron labeled cells, such as the lungs. In some cases, this limitation can be
avoided by acquiring a pre-and post-iron image and determining the change in signal
between the two acquisitions [87]. In addition, past studies have shown that iron oxides
have a high R1 relaxivity that can lead to an increase in signal by using a T1-weighted
pulse sequence with minimum echo time. Positive MR contrast has been demonstrated with
both USPIOs and SPIOs and is becoming a common application for anatomies that
naturally appear dark [118-120].

Another important limitation that needs to be considered when using iron-based cellular
MRI is the difficulty in quantification [120-121]. Since the void created by the iron oxide
is larger than the cell itself, it is quite difficult to determine the exact number of cells in a
given area when many cells are present. Regardless, a number of different approaches have
been developed to try to estimate the number of cell present by indirectly measuring the
amount of signal loss produced by iron labeled cells. This has included counting the
number of signal voids, measuring the percentage of black pixels in a particular region of
interest, or measuring the amount of contrast produced by iron labeled cells known as
fractional signal loss [87, 109, 120-123]. Others have also used T2/T2* relaxation rates to
estimate the amount of iron in a given area [124].
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1.5

Reporter gene imaging

In the last few decades, there has been significant progress in developing methods to stably
track proliferating cell populations in vivo over time. Unlike iron-oxide nanoparticles that
can be diluted through cell division, reporter gene based tracking involves engineering cells
to stably express a transgene that makes a product that can be detected with a particular
imaging modality. The inserted transgene will be passed to daughter cells, and thus will
permit longitudinal tracking of both dividing and non-dividing cell populations. Reporter
genes have most commonly been used for fluorescence microscopy studies of cultured
cells. In 2008, the discovery and development of fluorescent reporter genes (GFP and its
variants) was recognized with the chemistry Nobel prize to Drs. Roger Tsien, Osamu
Shimomura and Martin Chalfie. However, in the last few decades with the development of
whole-body small animal scanners, optical fluorescence and bioluminescence imaging
(BLI) reporters have been used extensively for tracking various cell types in small animal
models [125-131]. Moreover, since the early 2000s there has been many reporter genes
developed for tracking of cells with clinically-relevant imaging modalities such as PET,
SPECT, MRI and photoacoustic imaging [132-138]. Importantly, a landmark paper
recently described the use of reporter gene-based tracking of therapeutic T cells in glioma
patients, marking the first use of reporter genes to track a cellular therapeutic in the clinic
[139].
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1.5.1 Bioluminescence imaging
Bioluminescence imaging (BLI) was first described by Contag and colleagues in 1995
[140]. Since then, many groups have used BLI to track a variety of cell types in small
animal models. BLI has been adapted by cancer researchers as a valuable cell tracking tool
due to its high sensitivity, relatively low cost, and ability to differentiate between dead and
viable cell populations. Furthermore, BLI has high specificity as the signal acquired is a
direct measure of engineered cells [131].

To track transplanted cells, cultured cells are typically engineered to stably express a
luciferase transgene, most commonly Firefly luciferase (FLuc) or Renilla luciferase
(RLuc), which reacts with the corresponding substrate (D-luciferin for Firefly luciferase or
h-coelenterazine for Renilla luciferase). The enzymatic reaction produces light as a product
of enzyme-based oxidation of the substrate and photons are collected by a highly-sensitive
cooled charge coupled device (CCD) camera that converts photons into electrons after
striking silicon wafers [141] (Figure 1.4). To generate an image, CCD cameras spatially
encode the intensity of incident photons into electrical charge patterns and the signal
generated can be overlaid onto a white light image, an X-Ray or CT image for anatomical
reference. Firefly luciferase is most commonly used since the reaction also requires ATP
and oxygen to produce light and as a result, only viable cells produce signal. It also has a
red-shifted emission spectrum compared to Renilla luciferase so allows for better light
penetration out of deep tissues [130-131]. In 2004, Bhaumik and colleagues showed that
Firefly and Renilla luciferase have orthogonal substrates, demonstrating a lack of cross
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reactivity and thus, the ability to monitor the fate of two engineered cell populations
independently in the same animal [142]. In this thesis, we use both a red-shifted Firefly
luciferase from Luciola italica and Renilla luciferase 8 from Renilla reniformis to track
two different cancer cell populations in vivo using longitudinal BLI.
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Figure 1.4 Schematic of BLI protocol: Luciferase expressing cells are implanted into
the animal prior to imaging. Engineered cells will react with the corresponding
substrate and produce light as a product of oxidation. Emitted photons are collected
by a cooled CCD camera.
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1.5.2 BLI of cancer models
Perhaps the most commonly used application of BLI is to track the growth, dissemination,
and viability of cancer cells in mice during both normal tumour progression and in response
to treatment(s). Tumour burden of subcutaneous tumours has traditionally been monitored
using manual caliper measurements. While this technique is quick and relatively
inexpensive, it however does not account for areas of necrosis or edema within the tumour,
which can accumulate upon treatment without any change in tumour size. Additionally,
caliper measurements are only relevant to subcutaneous tumour models, which are not as
relevant as orthotopic models, and caliper measurements are also not a feasible option for
assessing metastatic tumour burden in deep tissues. As an alternative, many groups have
shown that BLI can provide rapid throughput measurements of tumour growth and
regression in animals over time [143-157]. For example, Jenkins and colleagues
demonstrate the ability to monitor both primary and spontaneous metastatic tumour burden
noninvasively with BLI. They implanted luciferase expressing colon cancer cells
subcutaneously into mice that consistently produce metastases in both the lungs and lymph
nodes. They were able to show correspondence between the frequency and size of
metastases detected in vivo with ex vivo imaging of excised lungs and lymph nodes [148].

BLI has also been employed to evaluate treatment response in vivo. Rehemtulla et al.,
showed that the survival of FLuc expressing gliosarcoma cells in rats can be noninvasively
monitored following treatment with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU). They
compared serial anatomical MRI tumour volume measurements with BLI photon flux over
time and demonstrate that both modalities yielded similar results, supporting the use of
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BLI as an effective tool for evaluating treatment response in living subjects [152].
Furthermore, in recent years it has been shown that FLuc BLI may be superior to other
imaging modalities in assessing treatment response since it can uniquely provide
information on cellular viability. While imaging modalities including MRI and CT are
useful for measuring changes in tumour volume following treatment, cancer cell death may
occur much sooner than changes in tumour size. Thus, the high sensitivity of BLI as well
as the ability to quantify only viable tumour cells, makes it a powerful complementary tool
to evaluate early changes in tumour viability. In breast cancer models, BLI has been used
extensively to evaluate the treatment effects of numerous therapies including but not
limited to combretastatin A4 phosphate, trastuzumab, lapatinib, rapamycin, and
cyclophosphamide [149-150]

1.5.3 Limitations of BLI
While BLI has significant value as a noninvasive cell tracking technology, it has some
important limitations to consider. The most detrimental in studying a cancer metastasis
model is the depth limitation. While BLI signal can be overlaid onto a brightfield or X-Ray
image for anatomical reference, it is a two-dimensional modality and does not offer the 3dimensional high-resolution images that MRI can [131, 132, 143]. Currently, there is not a
way to determine the depth of a tumour within the body based on the signal acquired with
most BLI systems. In recent years, three dimensional (3D) BLI systems have been
developed with the capability to overlay BLI signal with a 3D CT image set; however, due
to the increased cost, time required to acquire such a dataset, and the ability to image only
one animal at a time during 3D image collection, these systems have not been readily used.
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BLI signal relies on the availability of substrate and in the case of FLuc, other co-factors
such as ATP, magnesium, and oxygen. This can produce a false negative effect in the areas
that the substrate cannot easily accumulate into such as the brain, or in tumours that may
have compromised vasculature, again limiting access to substrate [147]. In addition, since
BLI is a measure of light output there can be an attenuation effect such that light is absorbed
or scattered by tissue, with hemoglobin being the main absorber of light within tissues
[141]. This can be seen in subcutaneous cancer models whereby scabbing forms on the
surface of large tumours and BLI signal is seen surrounding the scab [152]. This is more
confounding in metastatic models, due to the inability to readily visualize areas of
hemorrhage or necrosis that may be limiting light output. Thus, the use of several imaging
modalities together may overcome the inherent limitations of using only a single modality.

1.5.4 Benefits of multimodality imaging
As mentioned, multimodality imaging may provide a solution to overcome the limitations
of using each modality independently. Technologies such as BLI and PET are commonly
used to collect information on the biology of cells or groups of cells (their viability, tumour
metabolism, etc.) while modalities such as MRI and CT can provide valuable anatomical
information. Additionally, cellular or molecular MRI can enable visualization of molecular
biomarkers, cells, or therapeutic drugs. By using a combination of these technologies, we
can improve and expand the scope of information available regarding a certain disease state
[146, 151, 157].
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In a recent study by Le et al., the utility of combing BLI with multiparametric MRI
(mpMRI) was investigated for characterizing an orthotopic rat model of glioblastoma.
They showed that T1 and T2 weighted MR measurements of tumour volume continued to
increase up until endpoint (day 18), while on average, BLI signal peaks at day 11 and then
plateaued. Immunostaining confirmed the presence of both necrotic and hypoxic regions
in the majority of tumours, which is likely responsible for the decrease in BLI signal at
later timepoints [151]. Similarly, Fritz and colleagues demonstrated the advantages of
combing micro CT with BLI to evaluate early tumour-bone interaction in a mouse model
of tumour osteolysis. They found luciferase expressing tumour cells could be detected with
BLI as early as two days post implantation while the first clinical signs did not appear until
three weeks post injection. Furthermore, BLI measurements revealed an exponential
increase in BLI signal after two weeks, while micro CT measurements suggested a decrease
in bone density and bone mineral content as early as seven days [157]. These studies
highlight the value in using complementary modalities to obtain a more complete picture
of disease progression in preclinical models. Parts of this thesis explore the advantages of
combining cellular MRI and BLI in tracking the fate of metastatic cancer cells in vivo.

1.6

Purpose of Thesis

This thesis uses MRI and BLI techniques to study the mechanisms that influence breast
cancer metastasis. The objectives of this work were to develop a multimodality imaging
model to better visualize the stages of the metastatic cascade noninvasively using a mouse
model of breast cancer brain metastasis and to apply these imaging tools to study two
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potential mechanisms of cancer metastasis: concomitant tumour enhancement and tumour
self-homing.

1.6.1

Hypotheses

1. Bioluminescence imaging will complement our current iron-based cellular MRI tools
by allowing rapid throughput screening and longitudinal measurements of cell
viability.
2. In an immune competent mouse model of breast cancer metastasis, the presence of a
primary tumour will inhibit the growth of metastasis.
3. Systemically administered CTCs will preferentially home to and effectively treat
previously established disseminated breast cancer metastases throughout the mouse
body.

In Chapter 2, cellular and conventional MRI techniques were combined with serial BLI to
noninvasively track the fate of single breast cancer cells from their initial arrest in the brain
to the formation of overt tumours. This chapter was published in Scientific Reports
(Parkins KM, et al., “A multimodality imaging model to track viable cancer cells from
single arrest to metastasis” Scientific Reports. October 2016).

In Chapter 3, we used MRI and BLI to investigate the impact of a primary breast tumour
on the growth of secondary tumours in an immune competent mouse model of breast cancer
metastasis. In this work, we demonstrated concomitant tumour enhancement whereby the
presence of the primary tumour stimulated the growth of secondary metastases both in and
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outside of the brain. This work was published in Scientific Reports (Parkins KM, et al.,
“Multimodality cellular and molecular imaging of the impact of a primary tumor on
metastatic growth in a syngeneic mouse model of breast cancer brain metastasis”
Scientific Reports. June 2018)

In Chapter 4, using dual-luciferase BLI, we demonstrated the ability of experimental CTCs
to efficiently home to and treat primary tumours and disseminated breast cancer metastases
throughout the mouse body. This chapter is in preparation for submission.
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Chapter 2

2

A multimodality imaging model to track viable breast cancer
cells from single arrest to metastasis in the mouse brain

Purpose: Cellular MRI involves sensitive visualization of iron-labeled cells in vivo but
cannot differentiate between dead and viable cells. Bioluminescence imaging (BLI)
measures cellular viability, and thus we explored combining these tools to provide a more
holistic view of metastatic cancer cell fate in mice. Methods: Human breast carcinoma
cells stably expressing Firefly luciferase were loaded with iron particles, injected into the
left ventricle, and BLI and MRI were performed on days 0, 8, 21 and 28. Results: The
number of brain MR signal voids (i.e., iron-loaded cells) on day 0 significantly correlated
with BLI signal. Both BLI and MRI signals decreased from day 0 to day 8, indicating a
loss of viable cells rather than a loss of iron label. Total brain MR tumour volume on day
28 also correlated with BLI signal. Conclusion: Overall, BLI complemented our sensitive
cellular MRI technologies well, allowing us for the first time to screen animals for
successful injections, and, in addition to MR measures of cell arrest and tumor burden,
provided longitudinal measures of cancer cell viability in individual animals. We predict
this novel multimodality molecular imaging framework will be useful for evaluating the
efficacy of emerging anti-cancer drugs at different stages of the metastatic cascade.
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2.1

Introduction

Breast cancer is the second most common cancer in both American and Canadian women1.
The majority of breast cancer-associated mortality is due to metastasis; the dissemination
of cancer cells from the primary tumour to other parts of the body, rather than the presence
of a primary tumour. Therefore, the clinical need to better understand and prevent breast
cancer metastasis is high.

A number of in vivo imaging modalities can be used to measure tumour size, location and
metastatic burden such as positron emission tomography (PET), ultrasound (US), magnetic
resonance imaging (MRI), computed tomography (CT), single photon emission computed
tomography (SPECT) and optical imaging. Among these, MRI continues to be one of the
most employed modalities for studying cancer due to its high resolution and soft tissue
contrast without the use of ionizing radiation2.

Cellular MRI is an established tool to non-invasively visualize and track specific cell
populations in vivo. This technique uses iron oxide nanoparticles to label cells in culture or
in situ, enhancing their detectability by MRI3. The presence of intracellular iron causes a
distortion in the magnetic field which leads to signal loss in iron-sensitive images3.
Typically, millions of intracellular ultrasmall iron oxide particles (USPIOs) are needed to
be detected by MRI, however Shapiro et al. were the first to show that single, micron-sized
iron particles (MPIOs) can be loaded into cells and allow for single cell detection4. Wu et
al. showed that these particles can also be used to label in situ for successful tracking of
immune cells5. Although the amount of iron within these particles is significantly more
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than in the USPIOs, many cellular MRI studies have found that there is minimal impact on
cell function or phenotype6-8. While we and others have used cellular MRI extensively in
various scenarios, this technology has its limitations. First, is its limited ability to
definitively differentiate between dead and viable cells. Furthermore, when a cell dies the
iron label may be transferred to phagocytic bystander cells leading to false positive imaging
results9. This was demonstrated by Winter et al. who injected both dead and living ironlabeled human epicardium-derived cells (EPDCs) into the infarcted heart of immune
compromised mice10. The aim was to distinguish viable from dead cells by following the
hypointensity of signal voids over time. They found that a difference could not be seen
between signal intensity, void number, size or localization of live cells that migrate to the
infarcted area, and dead cells that are taken up by macrophages or other bystander cells10.
Thus, a complementary imaging tool to cellular MRI that could provide direct measures of
cellular viability over time would enable a more complete picture of cell fate in preclinical
models.

Similar to cellular MRI technology, bioluminescence imaging (BLI) with the reporter
Firefly luciferase (FLuc) has been adapted by many researchers as a valuable cell tracking
tool in preclinical models of cancer metastasis. The intensity and location of the
bioluminescent signal can provide insights into the biology of neoplastic cells, with respect
to their biodistribution and proliferative potential. FLuc BLI requires adenosine
triphosphate (ATP) as a cofactor and so the BLI signal is directly proportional to the
number of viable cells at a particular location11. This has been shown to provide
corresponding information to tumour volume measurements with more structure-based
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imaging such as CT or MRI. This can be crucial in models of treatment response where the
size or morphology of a tumour may not change but the amount of viable tissue within the
tumour will be altered12. Similarly, when a tumour naturally becomes necrotic as it
becomes larger, volume measurements can overestimate the number of viable cancer
cells12. Furthermore, BLI is a highly sensitive technology that can enable the visualization
and quantification of cancer cells at a stage where tumours are not yet detectable by these
other relatively less affordable and less sensitive imaging modalities13. Given its high
sensitivity and ability to provide measures of cellular viability, in this study we evaluated
whether BLI can be used in conjunction with cellular MRI to follow cancer cell fate from
their initial arrest in the brain to the formation of overt tumors in a well-established mouse
model of breast cancer metastasis. We demonstrate that BLI complements well with our
sensitive cellular MRI technologies, allowing us for the first time to get direct longitudinal
measures of whole-brain single cell arrest, tumour volumes, and cancer cell viability,
providing a more holistic view of transplanted cancer cell fate in living subjects.
Importantly, combining of these imaging technologies should be broadly applicable to
numerous preclinical models of experimental metastasis.

2.2

Materials & Methods

2.2.1 Cell Labelling and Transduction Procedure
Brain seeking human breast carcinoma cells (JIMT1-BR3) were engineered to stably coexpress FLuc and GFP following transduction with an LVP020 lentiviral vector
(GenTarget Inc., CA, USA). These cells were transduced and generously gifted by Dr.
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Patricia Steeg’s lab. Cells were maintained in DMEM containing 10% FBS at 37°C and
5% CO2. For iron labeling, 2 x 106 cells were plated in a 75cm3 flask, supplemented with
DMEM containing 10% FBS, and allowed to adhere for 24 hours. Then cells were
incubated for an additional 24 hours with 10mL media containing 25g/mL of MPIO beads
(0.9 um in diameter, 63% magnetite, labeled with Flash Red; Bangs Laboratory, Fishers,
IN, USA). Cells were washed once in the flask with Hanks balanced salt solution (HBSS)
and then trypsinized with 0.25% Trypsin-EDTA. The cells were then collected and
thoroughly washed three more times with HBSS to remove unincorporated MPIO before
cell injection and in vitro evaluation.

2.2.2 In Vitro Studies
To evaluate the relationship between cell number and BLI signal, cells were seeded in 24well plates in 0.5 mL of growth medium at concentrations of 5 x 103, 1 x 104, 2 x 104 and
5 x 104 cells per well. Cells were allowed to adhere for 24 hours and then 5L of D-luciferin
(30mg/mL; Perkin Elmer) was added to the growth medium 5 minutes prior to BLI using
a hybrid optical/Xray scanner (In Vivo FX PRO; Bruker formerly Kodak).

To evaluate if MPIO labeling effects BLI signal, cells were seeded in 24-well plates in
2mL of growth medium with 1 x 104 cells per well. Cells were allowed to adhere for 24hr
and then 25g/mL of MPIO was added to the growth medium for half of the wells. Cells
were then incubated for an additional 24hr before 5L of D-luciferin (30mg/mL) was
added for BLI.
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2.2.3 Animal Model
The animals were cared for in accordance with the standards of the Canadian Council on
Animal Care, and under an approved protocol of the University of Western Ontario’s
Council on Animal Care. To deliver MPIO-labeled FLuc/GFP+ cells into the brain,
1.75x105 cells were injected into the left ventricle of 12 female nu/nu mice (6 –7 weeks
old; Charles River Laboratories, Wilmington, MA, USA). Cells were suspended in 0.1mL
of HBSS and image-guided slow injections into the left ventricle were performed using a
Vevo 2100 ultrasound system (VisualSonics Inc.).

2.2.4 Animal Work Design
Figure 2.1 illustrates the 4-week timeline of our in vivo multimodality imaging model.
Twelve mice received intracardiac injections of 1.75x105 MPIO-labeled JIMT1-BR3FLuc/GFP+ cells on day 0. BLI signal was detectable one-hour post injection and was used
to differentiate between mice that had a successful intracardiac injection and mice that did
not. Mice that did not have successful injections were excluded from the remainder of the
study. Mice that had successful injections moved onto day 0 MRI four hours post injection.
These mice were then imaged with both BLI and MRI on days 8, 21 and 28. After endpoint
imaging, one mouse was sacrificed for cryofluorescence imaging and the rest were
sacrificed for histology.
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Figure 2.1 Experimental design for in vivo imaging: Illustration of MRI, BLI and
fluorescence cryo-imaging of metastases in mice with intracardiac injection of human
breast carcinoma cells. Original image courtesy of Chelsey Gareau.
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2.2.5 BLI Procedure
All in vivo BLI was performed on a hybrid optical/Xray scanner (In Vivo FX PRO; Bruker
formerly Kodak). Mice were anesthetized with isoﬂuorane (2% in 100% oxygen) using a
nose cone attached to an activated carbon charcoal filter for passive scavenging.
Approximately one hour following cell injection whole body BLI imaging was used to
screen mice for successful intracardiac injection on day 0. Only mice with BLI signal from
the brain proceeded to MRI (i.e., only mice with successful intracardiac injections). On
days 0, 8, 21 and 28, mice received 150 L of D-luciferin (30mg/mL) intraperitoneally and
BLI images were captured every 5 minutes for up to 35 minutes.

2.2.6

MRI Procedure

All MRI scans were performed on a 3T GE clinical MR scanner (General Electric) using a
custom-built gradient coil and a custom-built solenoidal mouse brain radiofrequency coil
3,14

. Mice were anesthetized with isoﬂuorane (2% in 100% oxygen) using a nose cone

attached to an activated carbon charcoal filter for passive scavenging and images were
obtained using a 3D balanced steady state free precession (bSSFP) imaging sequence [Fast
Imaging Employing Steady State Acquisition (FIESTA) on the GE system] which has been
previously optimized for iron detection15. Mice were imaged on days 0, 8, 21 and 28. The
scan parameters for days 0 and 8 were: repetition time (TR) = 8ms, echo time (TE) =4ms,
bandwidth (BW) = 41.7kHz, flip angle (FA) = 35 degrees, averages (NEX)= 2, phase
cycles=4, matrix = 150x150. Total scan time was approximately 15 minutes per mouse.
For days 21 and 28, a longer scan time was required for tumour detection and so imaging
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parameters were: TR=10ms, TE=5ms, BW= 12.5kHz, FA=35 degrees, NEX=2, phase
cycles=8, matrix= 150x150. Total scan time was approximately 35 minutes per mouse.

2.2.7 Image Analysis
Brain BLI signal was measured using region-of-interest (ROI) analysis using the Bruker
Molecular Imaging Software. An ROI was drawn around the brain, the mean photon flux
(photons/second/mm2) was measured, and the peak value over the 30-minute imaging
session was used for each mouse at each time point. MRI images were analyzed using
OsiriX software (Pixmeo, SARL, Bernex, Switzerland). The number of dark pixels within
the total brain volume was also determined from day 0 images; The brain was outlined as
a region of interest where a threshold value is set based on the mean value of signal void
2 standard deviations. The total number of black pixels under this threshold value was
obtained from the entire tumour volume signal intensity histogram. For days 0 and 8
images, signal voids were also manually counted in every 8th slice. The sum of all slices
was then multiplied by 4 to account for a standard signal void that goes through an average
of two slices. For days 21 and 28, brain metastases were manually traced by a single
observer. 3D tumor volumes were reconstructed using the OsiriX volume algorithm from
the manual segmentation of a region of interest around each tumor boundary in every
bSSFP image slice for each mouse.

2.2.8 Histology
At endpoint, mice were sacrificed by pentobarbital overdose and perfusion fixed with 4%
paraformaldehyde. Mouse brains were removed and cryopreserved in ascending

69

concentrations of sucrose (10, 20, and 30% w/v) in distilled water for 1 hour each. Brains
were immersed in optimal cutting temperature (OCT) compound, oriented in a sectioning
plane parallel to that of MRI, and frozen using liquid nitrogen. Contiguous 10-m frozen
sections were collected and stained using the following: hematoxylin and eosin (H&E) to
visualize tumour morphology, Firefly luciferase antibody (Abcam Inc., Cambridge,
MA,USA; product # ab21176, dilution factor 1:1000) to identify luciferase positive cells,
and Perl’s Prussian blue (PPB) staining to visualize iron. Stained sections were imaged
using a Zeiss 510 laser scanning confocal microscope and GFP-positive cancer cells were
also imaged.

2.2.9 Cryo-Fluorescence Imaging
After endpoint MR imaging (day 28), one mouse was sacrificed by pentobarbital overdose
and then flash frozen in OCT freezing medium by liquid nitrogen immersion. The entire
mouse was sectioned and optically imaged every 50μm using a CryoViz TM (Bioinvision
Inc., Cleveland, OH) cryo-imaging device. Block-face images were collected with an in
plane resolution of 10.5 x 10.5 μm2. Brightfield and fluorescent images were acquired,
stitched together and visualized using proprietary software (Bioinvision Inc).

2.2.10 Statistics
We evaluated the effect of MPIO labeling on BLI signal in the JIMT1-BR3/FLuc-GFP cell
line using a two-tailed t-test. Pearson correlational analysis of cell number to photon flux
in culture was performed as well as on in vivo BLI and MRI data on days 0 and 28. For all
tests, a nominal p-value <0.05 was considered statistically significant.
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2.3

Results

2.3.1 In Vitro Studies
Figure 2.2A shows the JIMT1-BR3/FLuc-GFP cell line was efficiently labelled with
MPIO. The Perl’s Prussian blue stain shows intracellular iron in blue within the breast
cancer cells that appear pink. JIMT1-BR3/FLuc-GFP cells were seeded at 5x103, 1x104,
2x104, and 5x104 cells per well and BLI was performed. A significant positive correlation
was seen between the number of JIMT1-BR3/FLuc-GFP cells seeded per well and BLI
signal (R2 =0.928). More specifically, as cell number increased, BLI signal also increased
(Figure 2.2B, 2.2C). There was no significant difference in BLI signal detected in cells that
were labeled with MPIO (M= 2.00 x 107  5.17 x 106 p/s/mm2) and cells that were not
labeled (M= 2.18 x 107  5.21 x 106 p/s/mm2) (ns, p value =0.82; Figure 2.2D, 2.2E). This
suggests that MPIO labelling has no significant quenching effect on BLI signal. These
results are from three independent experiments with three replicates of each condition.
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Figure 2.2 In vitro experiments: a) Perl’s Prussian blue stain identifies iron labelled
cells in blue (scale bar x 100). b) JIMT1BR3-Fluc/GFP+ cells seeded at various
concentrations c) A strong linear correlation is seen between cell number and BLI
signal; R2 =0.928 d) MPIO labeled JIMT1BR3-Fluc/GFP+ cells (L) and non-labeled
JIMT1BR3-Fluc/GFP+ cells (R). e) There was no significant difference in BLI signal
detected in cells that were labeled with MPIO and cells that were not labeled (ns, p
value =0.82). These results are representative of three experiments with three wells of
each condition.
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2.3.2 In Vivo Studies
Figure 2.3 shows image data from day 0. On day 0, iron labeled cells were visualized as
signal voids by MRI, distributed throughout the brain (Figure 2.3A). On average, 609 98
discrete, signal voids per brain were quantified throughout the brains in MRI images from
the nine animals that had successful injections of 1.75x105 MPIO-labeled cells. As
mentioned, BLI signal was also detected in the brain of these nine mice on day 0 (Figure
2.3B). Three of twelve mice did not have a successful intracardiac injection and showed
signal in other organs such as the lungs or abdominal cavity but not in the brain. These
mice were excluded from the remainder of the study. Figure 2.3C shows that the number
of signal voids measured on day 0 by MRI showed a significant correlation with BLI signal
in the brain on day 0 (R2=0.75, p < 0.01). Percent black pixels were also measured from
day 0 MRI images with the average percent black pixels within the whole brain being
3.35%; and showed a significant correlation with day 0 BLI signal in the brain (R2=0.74,
p < 0.01) (Figure 2.3D).
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Figure 2.3 Day 0 Imaging: a) single arrested cells could be visualized as signal voids
(blue arrows) in day 0 MR images. b) BLI signal was detectable in the brain on day
0. c) A significant correlation was found between total number of signal voids
measured from day 0 MRI scans and day 0 BLI signal in the brain (R2=0.75, p < 0.01).
d) A significant correlation was found between total percentage of black pixels
measured from day 0 MRI scans and day 0 BLI signal in the brain (R2=0.74, p < 0.01).
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Figure 2.4A shows imaging data over time and illustrates the MRI and BLI signal loss and
recurrence over time with tumour development. Notably, on day 8, there were few to no
voids seen by MRI and no detectable BLI signal in the brain; this is because the majority
of cancer cells die and are cleared and those that remain are below our current BLI detection
threshold. On day 21, three of nine mice showed BLI signal in the brain as well as small
tumours detected by MRI. The remaining six mice did not have detectable tumours with
either MRI or BLI at day 21. On day 28, these three mice had increased BLI signal and
larger brain metastases detected by MRI.

When we graph BLI signal over time, we found that the signal dropped at day 8 when the
cells were cleared but returned again when tumours started to form by day 21 (Figure 2.4B).
A one-way ANOVA was performed and BLI signal in the brain was found to be
significantly different at all time points (p < 0.0001).
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Figure 2.4 MRI and BLI over time a) Representative BLI (top) and MRI images
(bottom) of one mouse imaged on days 0, 8, 21 and 28; blue arrow shows signal void
progressing into tumour b) BLI signal in the brain over time. This graph is
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representative of 8 mice that made it to endpoint. A one-way ANOVA was performed
and all time points were found to be significantly different (p < 0.0001).
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Figure 2.5 shows image data from day 28. One mouse had to be sacrificed after day 21
imaging and so day 28 data is representative of eight mice. By day 28, brain metastases
appeared as regions of hyperintensity by MRI and BLI signal was detected in the brains of
all eight mice that had made it to endpoint (Figures 2.5A, 2.5B). In BLI images, six out of
eight mice also showed metastases in areas other than the brain. Total brain tumour burden
measured by MRI at endpoint (day 28) showed a significant correlation with BLI signal in
the brain on day 28 (R2=0.80, p < 0.01) (Figure 2.5C).
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Figure 2.5 Day 28 Imaging: a) Brain metastases (blue arrows) appear as region of
hyperintensity in day 28 MR images. b) Tumours were also detected using BLI on
day 28. c) A significant correlation was found between total brain tumour burden
measured by MRI at endpoint (day 28) and BLI signal in the brain (R2=0.80, p < 0.01).
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2.3.3 Histology and Whole-mouse Cryo-fluorescence Imaging
Mice were sacrificed 28 days after intracardiac cell injection. Dual fluorescence
microscopy of immunostained sections demonstrated that the location of luciferase positive
cells (labelled with red fluorescence) corresponded with the location of GFP expression
(seen in green) (Figure 2.6). These dual labelled cells also corresponded well with tumours
seen in MR images suggesting that metastases are composed of the FLuc-GFP positive
cells. In one mouse, the presence of tumours was also conﬁrmed using cryo-fluorescence
which has the ability to perform whole-body brightfield and fluorescence imaging
throughout the entire mouse. Cryo-imaging allowed for the detection of metastases at day
28 in both the brain and other areas of the body (Figure 2.7). Some of the metastases seen
with cryo-imaging could be matched to MR tumours but not all of them; this is likely
because some were too small to be detected with MRI. Whole body cryo-imaging also
allowed for the localization of metastases seen with BLI. Due to light scattering and depth
limitations, we cannot be certain where within the body the BLI signal is coming from;
cryo-imaging allows us to further explore a region of signal and find out where exactly the
tumour is located within the mouse body.
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Figure 2.6 Fluorescence microscopy and immunohistochemistry: Firefly luciferase
stain (c,d) green fluorescence protein (a/c low magnification, b/d high magnification)
e) Corresponding MRI image

f) Merged luciferase and GFP images at high

magnification; blue arrows show tumour within whole slice image. Scale bars =
300um
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Figure 2.7 Cryoviz Imaging: (A) Brightfield image of cryoviz mouse imaged on day
28 (B) Fluorescence microscopy detects GFP+ brain tumours and body tumours in
same slice as brightfield image (C) Corresponding day 28 BLI and (D) Whole body
MRI (E) Brain metastases (blue arrows) in cryo-image and corresponding MRI slice
in the same orientation. Scale bar = 0.50mm
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2.4

Discussion

We have previously demonstrated that cellular MRI is a valuable cell tracking tool for
preclinical investigation of brain metastatic breast cancer. However, it has limited ability
to differentiate between dead and viable cells. Moreover, MRI can also provide measures
of tumor volume in mouse models but this can potentially overestimate the number of
viable cancer cells in those tumors. In this study, we have for the first time combined
cellular MRI with BLI to provide longitudinal measures of cellular viability and better
study the entire metastatic cascade, from initial arrest to tumor formation, in a wellestablished breast cancer brain metastases mouse model. BLI complemented our cellular
MRI techniques well, demonstrating for the first time that MR measures of early cell arrest
are indeed viable cancer cells, that the decrease in MR void number from day 0 to day 8 is
due to loss of arrested viable cells rather than loss of iron label, and that MR measures of
brain tumor volumes at day 28 correlate well with BLI measures of cellular viability,
indicating that tumors are mostly composed of viable cells in this model.

Past studies have found that the left cardiac ventricular delivery of cells is an ideal model
for monitoring in vivo single cell detection; this is due to the fact that the delivery to a given
organ is initially proportional to the percentage of cardiac output (%CO) to that organ. In
this case, the %CO to the brain is ~9.5% and therefore for an injection of 175,000 cells, we
can expect ~16,625 cells to be delivered to the brain microcirculation16. However, <1% of
these cells are expected to be retained in the brain by 2 hours post injection16. On average,
609 98 discrete, signal voids were visualized throughout the brain in day 0 MRI images.
The MPIO used to label the JIMT1BR3-FLuc/GFP cells affects the MR signal by creating
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a blooming effect. As a result, a signal void appears much larger than the cell itself; making
single cell detection feasible. It has been shown that a signal void is usually representative
of a single cell, however it can also be representative of two or three cells clumped
together3. Thus, the 400-700 cells we are detecting at day 0 may be closer to 1000 cells.

When compared to other imaging technologies, BLI is often characterized as relatively
inexpensive, user friendly and highly sensitive. As a result, BLI can be used as a highthroughput screening tool for cell tracking studies. In this study, we used BLI to screen for
successful intracardiac injections on day 0. Mice that did not have a successful injection,
did not have any bioluminescent signal detected in the brain and thus were excluded from
the study. Prior to developing this model, each mouse would need to undergo a day 0 MRI
scan to determine if the injection was successful by detecting arrested cells (i.e., signal
voids). BLI can also be used to guide experimental design as well as predict or evaluate a
region of interest in less developed animal models. In this study, whole body BLI allowed
for the detection of metastases at sites that we had not previously detected or evaluated.
Day 28 BLI images helped to predict suspected organs of metastasis for ex vivo analysis.
To achieve sufficient resolution to detect iron-labelled cells in the brain, within a suitable
scan time, only the brain is imaged with MRI and metastases in other parts of the body may
have been overlooked if they were not prominent.

While MRI and BLI have been used separately as measures of overall tumour burden,
primarily in models with singular tumours, the concurrent application of BLI and MRI to
studying the entire process of brain metastasis has not been performed. In this work, BLI
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allowed for repetitive, non-invasive, whole body imaging and MRI based measurements
were used to validate BLI measurements of single cell arrest and tumour burden in the
mouse brain. There was a significant linear relationship between tumour volume measured
by MRI and light output measured by BLI. Although our MRI based measurements may
be a result of both dead and live tumour cells, phagocytic bystander cells (for iron
measurements), and other tumour stromal cells, BLI signal is representative of viable
tumour cells only. The correspondence between modalities at day 28 suggests that our
metastases are made up of mostly viable cancer cells at this time point. If we had imaged
at a later time point the correlation between modalities may become weaker as tumours
progress and develop a necrotic core. Similarly, if treatment was given, a decrease in viable
tumour tissue will affect the correlation between our multimodality tumour burden
measurements. This is an important advantage of BLI when evaluating potential treatment
paradigms, as a tumour may not look anatomically different in early stages of treatment
but the amount of viable tissue within that tumour may change.

Cryo-imaging allowed for the detection of fluorescent micrometastases in the brain as well
as other places in the body. While food in the abdominal cavity creates some
autofluorescence this may be alleviated in the future using alfalfa-free diets. However,
tumours detected with cryo-fluorescence imaging that appear to be in the middle right
abdominal cavity and above the left hindlimb matched well with BLI images and appear
much brighter than the autofluorescence from the food. Like MRI, the cryo-imaging can
also allow us to localize and count the number of micrometastases in the brain where as
the BLI image gives us one individual measure for all combined tumours. Some brain
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metastases found in MR images matched our cryo-fluorescence images well while others
appeared too small to be detectable with MRI.

This study demonstrates how a multimodality imaging model that uses both MRI and BLI
can overcome the limitations of using each modality independently. Although BLI can
produce a measure of tumour burden within the brain, we are unable to collect information
on the number, size or distribution of tumours within the region of interest. This can be a
limiting factor in cancer metastasis models that use BLI only; numerous tumours or
arrested cells that are close in proximity appear as one large region of signal due to light
scattering, and at equivalent sizes tumours that are more superficial will appear to be
brighter than those that are located deeper. In contrast, MRI can detect individual ironloaded cells and provide information on tumour 3D location and size. These modalities
also complement each other at different time points throughout the experiment. Our current
BLI protocol was not sensitive enough to detect signal in the brain on day 8, even though
we know there are in fact viable cancer cells there (i.e., tumours formed in the brain and
signal voids were seen on day 8). Future work using newer luciferase substrates or BLI
machines with more sensitive CCD cameras could overcome this limitation17, 18. However,
our cellular MRI technology was able to detect the limited number of cells that persisted
in the brain on day 8. By day 21 tumours were easily detected by BLI in three of nine mice
however, these tumours were very small and thus difficult to find with MRI. Tumours with
minimal burden and MR contrast on day 21 may have been overlooked if BLI signal had
not predicted metastases prior to MRI imaging.
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2.5

Conclusion

In this work, we applied multimodality imaging to monitor the growth of metastatic breast
cancer cells in the brain from single arrested cells to overt tumours. BLI complemented our
sensitive iron-based cellular MRI technologies well, allowing us for the first time to get
direct longitudinal measures of whole-brain single cell arrest, tumour burden, and cancer
cell viability in the brain. Future work will extend these tools for whole-mouse MRI/BLI
of metastatic burden, which will be extremely valuable for enabling an improved
understanding of the fate of single cancer cells throughout the body and evaluation of
current and emerging treatment paradigms.
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Chapter 3

3

Multimodality cellular and molecular imaging of concomitant
tumour enhancement in a syngeneic mouse model of breast
cancer metastasis

Introduction: The mechanisms that influence metastatic growth rates are poorly
understood. One mechanism of interest known as concomitant tumour resistance (CTR)
can be defined as the inhibition of metastasis by existing tumour mass. Conversely, the
presence of a primary tumour has also been shown to increase metastatic outgrowth, termed
concomitant tumour enhancement (CTE). The majority of studies evaluating CTR/CTE in
preclinical models have relied on endpoint histological evaluation of tumour burden.
Objective: The goal of this research was to use conventional magnetic resonance imaging
(MRI), cellular MRI, and bioluminescence imaging to study the impact of a primary
tumour on the development of brain metastases in a syngeneic mouse model. Results:
Here, we report that the presence of a 4T1 primary tumour significantly enhances total
brain tumour burden in Balb/C mice. Using in vivo BLI/MRI we could determine this was
not related to differences in initial arrest or clearance of viable cells in the brain, which
suggests that the presence of a primary tumour can increase the proliferative growth of
brain metastases in this model. Conclusion: The continued application of our longitudinal
cellular and molecular imaging tools will yield a better understanding of the mechanism(s)
by which this physiological inhibition (CTR) and/or enhancement (CTE) occurs.
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3.1

Introduction

Breast cancer is the second leading cause of cancer related deaths in North America with
the majority of deaths due to metastasis, the dissemination of cancer cells from the primary
tumour to other parts of the body1. One of the most common, as well as most fatal sites of
metastatic growth for breast cancer patients is the brain, with the incidence of brain
metastasis increasing and prognosis remaining poor2. Improved knowledge regarding how
quickly cancer cells disseminate from the primary tumour and the rate of secondary
metastases development, as well as the mechanisms that control proliferation rate, are key
to developing new therapies to prevent or halt metastatic growth and prevent cancer
mortality.

The mechanisms that influence metastatic growth rates are poorly understood. One
mechanism of interest is concomitant tumour resistance (CTR), which describes the ability
of the primary tumour to restrict the growth of distant metastases3,4. The relevance of CTR
has been shown by numerous observations of the removal of a primary tumour being
followed by an abrupt acceleration of residual metastatic disease. CTR has been observed
in both breast cancer patients5 and animal models of breast cancer6. It has also been
observed in patients with other solid tumour types7,8. Conversely, it has been shown that
the presence of a primary tumour can likewise increase metastatic outgrowth, a
phenomenon coined concomitant tumor enhancement (CTE). However, in the clinic, very
few examples of CTE have been reported with most of them being related to suspected
regressions of hepatic and/ or pulmonary metastases following nephrectomy for renal cell
carcinoma9-12. While imaging has been used to describe CTR/CTE effects in patients13, the
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majority of studies evaluating CTR/CTE in preclinical models have relied on endpoint
histological evaluation of tumour burden14,15. The application of cellular and molecular
imaging tools will allow the non-invasive and longitudinal visualization of metastatic
progression to study CTR/CTE effects in vivo, which will ultimately yield better evaluation
of putative molecular mechanism(s) by which this physiological inhibition and/or
enhancement occurs. In turn, this may lead to new anti-metastatic therapeutics aimed at
these mechanisms and their non-invasive evaluation.

Previously, we applied cellular MRI techniques to study the impact of a primary tumour
on metastatic outgrowth in an immune deficient mouse model of experimental breast
cancer metastasis to the brain and demonstrated clear CTR effects in the brain16. Cellular
MRI involves pre-labeling cultured cancer cells with superparamagnetic iron oxide
nanoparticles prior to transplantation into mice. This labeling allows transplanted cells to
be tracked over time with iron-sensitive MRI techniques. Single cell imaging of cancer
cells arresting in the brain at the time of injection and of non-dividing, iron-retaining cancer
cells over time is achievable with this technique17. However, limitations of iron oxide based
cellular MRI are that there is limited ability to differentiate between dead and viable cells,
that it is possible for iron particles to be transferred to bystander cells such as macrophages
upon cell death, and that the iron particles are diluted during cell division leading to loss
of cell detection in proliferative cells. These limitations can be overcome using reporter
gene based cell tracking tools, since a stably expressed reporter gene is passed on to
daughter cells and will not be expressed in bystander cells. By engineering cells to express
a luciferase reporter, bioluminescence imaging (BLI) can provide a direct readout of cell
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viability in dividing cell populations. Overall, as recently described18, combining our
highly sensitive cellular MRI tools and BLI yields complementary information on the fate
of metastatic cancer cells in preclinical models. As others have pointed to a role of the
immune system in CTR/CTE and differences in primary tumour effects have been seen
across models of the same cancer type8, the purpose of this study was to apply our
multimodality imaging tools to study whether CTR/CTE effects are present in the
syngeneic 4T1 immune competent mouse model of breast cancer metastasis.

3.2

Methods

3.2.1 Cell Labelling and Transduction Procedure
The 4T1-BR5 cells were received from Dr. Patricia Steeg’s lab and engineered to stably
co-express red-shifted Luciola Italica luciferase (Red-FLuc) and green fluorescent protein
(GFP) using a commercial lentiviral vector (RediFect Red-FLuc-GFP; PerkinElmer, USA).
Cells were transduced and FACS sorted based on GFP expression using a FACSAria III
flow cytometric cell sorter (BD Biosciences). The resultant 4T1BR5-Red-FLuc/GFP cells
were maintained in DMEM containing 10% FBS and 1% antibiotics, at 37°C and 5% CO2.
For iron labeling, 2x106 4T1BR5-Red-FLuc/GFP cells were plated, and 24 hours later were
incubated with 25g/mL of micron-sized superparamagnetic iron oxide (MPIO) beads for
an additional 24 hours (0.9 m in diameter, 63% magnetite, conjugated with Flash Red;
Bangs Laboratory, Fishers, IN, USA). Cells were washed three times with Hanks balanced
salt solution (HBSS), collected and thoroughly washed three more times with HBSS to
wash off residual unincorporated MPIO before in vitro evaluation or injection into animals.
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3.2.2 In Vitro Studies
All in vitro results are from three independent experiments with three replicates of each
condition. To evaluate the relationship between cell number and BLI signal, 1x103, 5x103,
1x104, 1.5x105, and 5x105 4T1BR5-Red-FLuc/GFP cells were seeded in each well of 24well plates. Twenty-four hours later, 5 L of D-luciferin (30 mg/mL; Syd Labs, Inc., MA,
USA) was added to the growth medium and BLI images were collected 5 minutes later
using a hybrid optical/X-ray scanner (IVIS Lumina XRMS In Vivo Imaging System,
PerkinElmer). BLI signal was measured with region-of-interest (ROI) analysis using
LivingImage Software (Perkin Elmer). An ROI was drawn around each well to measure
the average radiance (photons/second/mm2/steradian), and the mean average radiance
across replicates was determined for each independent experiment.

To evaluate if MPIO labeling influenced BLI signal, 1.25 x 105 4T1BR5-Red-FLuc/GFP
cells were seeded in each well of a 24-well plate. Twenty-four hours later, 25g/mL of
MPIO was added for half of the wells. After an additional twenty-four-hour incubation
period, the media for all wells was replaced with fresh media without iron, 5L of Dluciferin (30mg/mL) was added for BLI, and BLI signal per well was analyzed as above.

Vybrant MTT proliferation assays were used to evaluate the effects of genetic engineering
on cell proliferation. 6.25x103 4T1BR5-Red-FLuc/GFP or naïve 4T1BR5 cells were
seeded in each well of 96 well plates and cells were evaluated 24 and 48 hours later. Twenty
microliters of MTT solution was added to each well and absorbance at 450nm was
measured

using

a

microplate

spectrophotometer
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(Fluoroskan

Ascent

FL,

ThermoLabSystems). Cell labeling efficiency was assessed by Perl’s Prussian blue (PPB)
staining, as previously described19.

3.2.3 Animal Model
Figure 3.1A illustrates the experimental mouse model used in this study. Animals were
cared for in accordance with the standards of the Canadian Council on Animal Care, and
under an approved protocol of the University of Western Ontario’s Council on Animal
Care (2014-026). Six to eight-week-old female BALB/c mice (n=32) were obtained from
Charles River Laboratories (Willington, MA, USA). Mice received a lower right mammary
fat pad (MFP) injection of either vehicle (HBSS; Control mice; n=16) or 300,000 unlabeled
4T1 cells (MFP mice; n=16). MFP tumour growth was evaluated by measurement with
calipers in two perpendicular dimensions, and the tumour volume was estimated using the
following formula volume = 0.52 (width)2(length), for approximating the volume (mm3)
of an ellipsoid

20, 21

. MFP tumours grew for either seven days (Small MFP) or 14 days

(Large MFP) prior to all mice receiving an intracardiac injection of 2x104 MPIO-labeled
4T1BR5-Red-FLuc/GFP cells in 0.1mL of HBSS. Injections were performed under image
guidance using a Vevo 2100 ultrasound system (VisualSonics Inc.).
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Figure 3.1 Experimental design of animal model: A) Experimental design of animal
model used for Small and Large MFP experiments B) On day 0, the number of
discrete signal voids, representing iron-labeled cells, that arrested in the brain on day
0 as well as brain BLI signal was not significantly different between mice with and
without a small MFP tumour. C) There were also no significant differences in cell
arrest for mice with large MFP tumours. D/E) All four groups of mice were not
significantly different from each other in MRI cell arrest at day 0 as well as BLI signal
in the brain at day 0. Data is presented as mean +/- SD.
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3.2.4 BLI Procedure
BLI was performed on days 0, 7 and 14 for all mice after intracardiac injection using a
hybrid optical/X-ray scanner (IVIS Lumina XRMS In Vivo Imaging System,
PerkinElmer). Mice were anesthetized with isoﬂuorane (2% in 100% oxygen) using a nose
cone attached to an activated carbon charcoal filter for passive scavenging. Anesthetized
mice received a 150 L intraperitoneal injection of D-luciferin (30 mg/mL) and BLI
images were captured for up to 35 minutes. On day 0, approximately one hour following
intracardiac injection, whole body BLI was used to screen mice for successful intracardiac
injection on day 0 and to measure brain BLI signal. Only mice with brain BLI signal
proceeded to MRI (i.e., only mice with successful intracardiac injections).

3.2.5

MRI Procedure

MRI was performed on a 3T GE clinical MR scanner (General Electric) using custom-built
gradient and solenoidal mouse brain radiofrequency coils22,23. Mice were anesthetized with
isoﬂuorane (2% in 100% oxygen) and images were obtained using a 3D balanced steady
state free precession (bSSFP) imaging sequence [Fast Imaging Employing Steady State
Acquisition (FIESTA) on the GE system], which has been previously optimized for iron
detection24. Small MFP and control mice were imaged on days 0, 7, and 14 and large MFP
and control mice on days 0 and 14 after intracardiac injection. The scan parameters for day
0 were: repetition time (TR)=8 ms; echo time (TE)=4 ms; bandwidth (BW)=41.7 kHz; flip
angle (FA)=35 degrees; averages (NEX)=2; phase cycles=4; matrix=150x150; field-ofview (FOV)= 1.5; resolution: 100 x 100 x 200 m; and scan time= 19.25 minutes. For days
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7 and 14, a longer scan time was required for tumour detection using the following imaging
parameters: TR=10 ms; TE=5 ms; BW=12.5 kHz; FA=35 degrees; NEX=2; phase
cycles=8; matrix=150x150; FOV=1.5; resolution=100 x 100 x 200 m; scan time=36.76
minutes. In addition, large MFP mice and corresponding control mice (n=16), a 3D bSSFP
imaging sequence was used to obtain high resolution MR images of the whole mouse body
on day 9 using a solenoidal whole-body radiofrequency coil. Sequence parameters were as
follows: TR=6.3 ms; TE=3.1 ms; BW=31 kHz; FA=35 degrees; NEX=2; phase cycles=8;
matrix=300 × 150; FOV = 60 × 30 mm; resolution=200 × 200 × 200 μm3; and scan time=
22 minutes. One large MFP mouse and one control mouse also had whole body MR scans
at endpoint (day 14) to allow us to match MR and BLI detectable metastases to wholemouse cryo-fluorescence images as described below.

3.2.6 Image Analysis
Brain BLI signal was measured with region-of-interest (ROI) analysis using LivingImage
Software (Perkin Elmer). An ROI was drawn around the brain, the average radiance
(photons/second/mm2/sr) was measured, and the peak value over the 35-minute imaging
session was used for each mouse at each time point. Whole body BLI signal was measured
the same way as listed above with the ROI drawn around the whole mouse body. MRI
images were analyzed using OsiriX software (Pixmeo, SARL, Bernex, Switzerland). For
days 0 and 7 images, total brain signal void number, representing iron labeled cancer cells,
was determined by manually counting voids in every MR slice. For day 14 images, brain
metastases were manually traced in every bSSFP image slice for each mouse and 3D
tumour volumes were reconstructed using the OsiriX volume algorithm.
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3.2.7 Cryo-Fluorescence Imaging
After endpoint MR imaging (day 14), one large MFP and one control mouse were
sacrificed by isoflurane overdose and then flash frozen in OCT freezing medium by liquid
nitrogen immersion. The entire mouse was sectioned and optically imaged every 50-μm
using a cryo-fluorescence imager (CryoVizTM; Bioinvision, Inc., Cleveland, OH). Blockface images were collected with an in-plane resolution of 10.5 × 10.5 μm2. Brightfield and
fluorescent images were acquired, stitched together and visualized using proprietary
software (Bioinvision, Inc).

3.2.8 Histology
At endpoint, the majority of mice (n=26) were sacrificed by isoflurane overdose and
perfused with 4% paraformaldehyde via the left ventricle. Mouse brains were removed and
cryopreserved in ascending concentrations of sucrose (10, 20, and 30% w/v) for 24 hours
each. Brains were immersed in optimal cutting temperature (OCT) compound, oriented in
a sectioning plane parallel to that of MRI, and frozen using liquid nitrogen. Contiguous 10m frozen sections were collected and select sections were stained with hematoxylin and
eosin (H&E). Stained sections were imaged using an Invitrogen EVOS FL Auto Cell
Imaging System and histological images were manually matched to MR slices using
anatomical landmarks such as the ventricles and MR-visible tumours. Fluorescence images
of 4T1BR5-Red-FLuc/GFP cancer cells were also collected on the same microscope and
matched to MR slices. Spleens were collected and weighed. Contiguous 10-m paraffin
embedded sections were collected, select sections were stained with H&E, and imaged
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using a Zeiss 510 laser scanning confocal microscope.

3.2.9 Statistics
A power analysis was performed using G*Power software to determine the appropriate
sample size for this study. All statistics were calculated using GraphPad Prism 4. A
Shapiro-Wilk normality test found that some of our in vitro data was not normally
distributed and thus, a non-parametric test (Mann-Whitney) was performed on proliferation
experiments. Pearson’s rank correlation was used to determine a relationship between cell
number and BLI signal. Student’s two-tailed unpaired t test was used to compare the other
in vitro experiments as well as between animal groups. A nominal p-value less than 0.05
was considered statistically significant.

3.3

Results

3.3.1 In Vitro Studies
4T1-BR5 cells were 85.4% transduced with a lentiviral vector and sorted to stably coexpress Red-FLuc/GFP (Suppl. 1A/B). The resultant 4T1BR5-Red-FLuc/GFP cells were
efficiently (>90%) labeled with MPIO prior to intracardiac injection (Suppl. 1C). There
was no significant difference in BLI signal detected in 4T1BR5-Red-FLuc/GFP cells that
were labeled with MPIO (2.14 x 107  1.37 x 106 p/s/mm2/sr) compared to those that were
not labeled (2.48 x 107  1.80 x 106 p/s/mm2/sr) (Suppl. 1D). Furthermore, a significant
positive correlation was detected between the number of 4T1BR5-Red-FLuc/GFP cells and
BLI signal (R2 = 0.98, p<0.01; Suppl. 2A). There were no differences in cellular
proliferation detected between naïve 4T1-BR5 and 4T1BR5-Red-FLuc/GFP cells (Suppl.
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2B). 4T1-BR5-Red-Fluc/GFP cells also showed no significant change in Red-Fluc
expression over multiple passages in culture (Suppl. 2C).

3.3.2 In Vivo Studies
We first looked at imaging data from the day of intracardiac injection (Day 0) shown in
Figure 3.1. Iron labeled cells were visualized in MR images as discrete signal voids
distributed throughout the mouse brain (Figure 3.1B, 3.1C). Across all 32 mice with a
successful intracardiac injection, an average of 98  5 discrete signal voids per mouse were
quantified throughout the brains in MR images. The number of discrete signal voids on day
0 was not significantly different between mice with (100 7 voids) and without (121  10
voids) a small primary MFP tumour (Figure 3.1D). Similarly, the number of discrete signal
voids on day 0 was not significantly different between mice with (86  5 voids) and without
(87  6 voids) a large primary MFP tumour (Figure 3.1D). BLI signal was also detected in
the brain of these thirty-two mice on day 0 (Figure 3.1B, 3.1C). We found no significant
difference in brain BLI signal between mice with (4.4x104  8.5x103 p/s/mm2/sr) and
without (4.7x104  7.8 x103 p/s/mm2/sr) a small primary MFP tumour, nor with (2.9x104 
6.8x103 p/s/mm2/sr) or without (3.3x104  8.7x103 p/s/mm2/sr) a large primary MFP tumour
(Figure 3.1E).

All MFP tumors were manually assessed with caliper measurements throughout the study.
We found a significant difference in Small MFP tumour volume between days 0 (time of
intracardiac injection; 138.8 12.11 mm3) and 14 (endpoint; 666.4 20.89 mm3; p<0.001).
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Similarly, we found a significant difference in Large MFP tumour volume between days 0
(308.4  9.14 mm3) and 14 (817.9  15.12 mm3).

For mice in the small MFP experiment we looked at imaging data over time and Figure 3.2
illustrates the MRI and BLI signal loss over time representing viable cancer cell clearance
in the brain for BLI as well as potential iron label dilution in MR images. The number of
signal voids in the brain significantly decreased from day 0 (109.9  7.58 voids) to 7 (7 
0.27 voids) for control mice and from day 0 (92.88  6.96) to 7 (7.75  0.70; p<0.0001;
Figure 3.2B) for small MFP mice. BLI signal in the brain also significantly decreased for
control mice from day 0 (5.1x104  5.8x103 p/s/mm2/sr) to 7 (1.5x104  3.6x103 p/s/mm2/sr)
and for small MFP mice from day 0 (4.4x105  8.5x103) to day 7 (2.9x105  9.8x103;
p<0.01; Figure 3.2C).
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Figure 3.2 Cell clearance imaging: A) BLI and MR imaging data illustrates the signal
loss over time with cell clearance in the brain of small MFP and control mice. B) The
number of signal voids in the brain decreases from days 0 to 7 as cancer cells are
cleared from the brain. C) BLI signal also decreases from day 0 to 7 as cancer cells
are cleared from the brain. Data is presented as mean +/- SD. * indicates p<0.05.
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At day 14, brain metastases appeared as regions of hyperintensity by MRI in all twentynine mice that made it to endpoint as well as two large MFP mice that had an early endpoint
of day 10 due to illness (Figure 3.3 - Small MFP group; Figure 3.4 – Large MFP group).
An additional mouse in the large MFP group had to be sacrificed at day 9 due to signs of
illness but endpoint MRI was not performed and thus this mouse was not included in our
endpoint analysis. Figures 3.3A, 3.4A show an MR slice from a representative mouse from
each group. MR image analysis revealed that mice with a small primary MFP tumour
(13.63  2.05 tumours) had significantly more brain metastases than control mice (6  0.84
tumours) (Figure 3.3C). We also found that mice with a small MFP tumour (2.38  0.55
mm3) had significantly higher total brain tumour volume than control mice (0.72  0.17
mm3) (Figure 3.3D). Similarly, we found that mice with a large primary MFP tumour (30
 2.22 tumours) had significantly more brain metastases than control mice (12  1.48
tumours) (Figure 3.4C). We also found that mice with a large MFP tumour (4.81  0.59
mm3) had significantly increased total brain tumour volume than control mice (1.65  0.44
mm3) (Figure 3.4D).

Figures 3B/4B show BLI images of a representative mouse from each group at endpoint
(day 14). All 13 MFP mice that made it to endpoint had BLI signal in the brain while only
13 of 16 control mice had signal in the brain. An additional 2 MFP mice (large) had BLI
signal in the brain at day 10 (day of sacrifice) which were included in our endpoint
measurements of brain tumour burden. BLI signal in the brain at endpoint was not
significantly different between mice with (1.1x105  5.1x104 p/s/mm2/sr) and without (4.3
x104  3.5x105 p/s/mm2/sr) a small MFP tumour (Figure 3.3E). However, BLI signal in the
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brain at endpoint was significantly different between mice with (5.9x104  2.2x104
p/s/mm2/sr) and without (1.1x104  4.7x103 p/s/mm2/sr) a large MFP tumour (Figure 3.4E).
All MFP and control mice had BLI signal in the body at endpoint. Similarly, whole body
BLI signal was not significantly different between mice with (1.2x107  5.9x106
p/s/mm2/sr) and without (4.5x106  2.5x106 p/s/mm2/sr) a primary MFP tumour (Figure
3.3F) or between mice with (3.1x105  1.7x105 p/s/mm2/sr) and without (1.2x105  7.9x104
p/s/mm2/sr) a large MFP tumour (Figure 3.4F).
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Figure 3.3 Endpoint imaging for small MFP mice: A) At day 14, brain metastases
appeared as regions of hyperintensity by MRI, and B) regions of BLI signal in the
brain and body. C) Mice with a primary small MFP tumor had significantly more
brain metastases than mice without a primary tumor. D) Mice with a primary tumor
had significantly more total brain tumor burden than mice without a primary small
MFP tumor. E/F) There were no significant differences in BLI signal in the brain or
body between mice with and without a primary small MFP tumour. Data is presented
as mean +/- SD. * indicates p<0.05; ** indicates p<0.01.
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Figure 3.4 Endpoint imaging for large MFP mice: A) At day 14, brain metastases
appeared as regions of hyperintensity by MRI, and B) regions of BLI signal in the
brain and body. C) Mice with a large MFP tumor had significantly more brain
metastases than mice without a primary tumor. D) Mice with a large MFP tumour
had significantly more total brain tumor burden than mice without a primary tumor.
E/F) Similarly, mice with a large MFP tumour had significantly more BLI signal in
both the brain and the body compared to control mice. Data is presented as mean +/SD. * indicates p<0.05; ** indicates p<0.01.
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3.3.3 Histology and whole-mouse cryo-fluorescence imaging
In one large MFP mouse, lung metastases were detectable in whole-body MR images but
not in the respective control mouse (Suppl. 3.3). In one small MFP mouse the presence of
tumours was also confirmed in ex vivo BLI (Suppl. 3.4). Coronal MR images show
corresponding orientation to BLI signal; in vivo and ex vivo whole body BLI were also
matched presenting signal in the abdominal region. Fluorescence microscopy demonstrated
that the location of 4T1BR5-Red-FLuc/GFP cells corresponded well with H&E as well as
hyperintense signal representing tumors in the corresponding MR slice (Suppl. 3.5). This
confirms that metastases detected with MRI contain 4T1BR5-Red-FLuc/GFP cells. In two
mice, the presence of tumors was also confirmed using cryo-fluorescence imaging which
has the ability to perform whole-body brightfield and fluorescence imaging throughout the
entire mouse. Cryo-fluorescence imaging allowed for the detection of metastases at day 14
in both the bone and other areas of the body (Figure 3.5). We were able to match some of
the metastases seen with cryo-imaging to MR tumours. Cryo-fluorescence imaging also
allowed for the localization of secondary metastases seen with BLI. Due to light scattering
and the depth limitation of BLI, we cannot be certain where within the body as well as the
number of metastases the signal is coming from; cryo-imaging allows us to further explore
a region of interest and find out exactly where the tumor is located. Finally, we found that
spleens from large MFP tumour-bearing mice (0.65  0.03g) were enlarged with
significantly higher weights compared to spleens collected from control mice (0.15 
0.01g) (p<0.0001; Figure 3.6A, 3.6B). Normal spleen histology was observed in control
mice but it was found that the spleens isolated from large MFP mice showed a reduction
in red pulp compared to control mice (Figure 3.6C).
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Figure 3.5 Cryoviz Imaging: In a mouse from the large MFP group we were able to
detect distant metastases (head circled in yellow; bone circled in blue) with BLI (A)
and match them to corresponding MR (B) and brightfield (C/E) and fluorescence
(D/E) cryoviz images.
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Figure 3.6 Observed splenomegaly: A/B) Spleens from large MFP tumor-bearing
mice were enlarged and significantly higher in weight(g) than spleens collected from
control mice. C) Normal spleen histology was observed in control mice (Top) but it
was found that the spleens isolated from large MFP mice showed a reduction in red
pulp (bottom) compared to control mice and normal spleen histology. Data is
presented as mean +/- SD. **** indicates p<0.0001.
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3.4

Discussion

Clinical and experimental evidence suggests that a primary tumour can both accelerate
(CTE) or retard (CTR) the growth of distant metastases4-14. In this study, we found CTE
effects in the syngeneic 4T1 model using multimodality imaging. The presence of a
primary MFP tumour increased the number and total volume of brain metastases as
measured with MRI and BLI (in the large MFP group). Secondly, this effect was amplified
when the primary tumour was larger at the time of secondary injection of experimental
metastatic cells. To our knowledge, this is the first report of multimodality imaging being
used to study the impact of a primary tumour on metastatic outgrowth in the 4T1 model.

In our previous studies in immune compromised mice (nu/nu) we found the presence of a
human primary breast tumour (MDA-MB-231) significantly inhibited the growth of MDAMB-231BR brain metastases (i.e., a CTR effect)16. For this study, MRI revealed fewer
brain metastases developed in mice with than without a primary tumour. Interestingly,
using cellular MRI, we also found that significantly more signal voids (representing nondividing cancer cells) persisted in endpoint images of mice that had a primary tumour
compared to mice that did not. This highlighted that a primary tumour can in part maintain
cancer cell dormancy and mitigate overt metastases formation, a potential new mechanism
for CTR. We could not assess endpoint signal void number in the current study due to the
very low number of cells arresting and remaining in the brain at endpoint. In future studies,
we could shorten the experimental timeline to enable a greater number of cells injected into
the heart, which in turn could result in more voids persisting at endpoint.

112

Our results between the two models suggests the immune system may play a role in
mediating CTR or CTE effects, as also suggested previously by others. Janik et al., found
that immune competent mice are first protected and then made more susceptible to the
growth of lung metastases by the presence of a progressively growing primary tumour7.
Similarly, Vaage et al., showed that immunity decreases around day 20 after implanting
tumour cells into mice and that this phenomenon was associated with an excess of tumour
antigen, and that after removal of the primary tumour immunity is quickly restored26. This
may provide support as to why we found an amplified CTE effect in our large MFP mice.
This cohort of mice had 14 days of primary tumour growth (compared to 7 days in small
MFP mice) before secondary injection, followed by 14 days of metastatic growth. This
theoretical 20-day period would fall fairly early (6 days) into the period of metastatic
growth, leaving these mice vulnerable to enhanced metastatic growth due to decreased
immunity. Whether the immune system is playing a significant role in the CTE effects seen
in this study could be determined by moving our 4T1/4T1BR5 model from BALB/c mice
into an immune compromised mouse (e.g., nu/nu), expecting either a CTR effect or a lesser
CTE effect than seen in the present study. Similarly, we may see a more significant CTR
effect by studying the MDA-MB-231/MDA-MB231BR model into more immune deficient
mice than used before (nu/nu) such as nod-scid-gamma (NSG) mice, or evaluating whether
a CTE effect might appear in humanized mice.

An immunological component to the CTE effects seen is also suggested from our findings
in the spleens from our animals. We found splenomegaly in tumour-bearing mice however,
this finding was associated with a reduction in red pulp and not differences in white pulp.
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Kirstein et al., found splenomegaly in tumour-bearing animals was associated with trilineage extramedullary hematopoiesis as well as a reduction in white pulp in their mouse
model of CTR14. Other groups have also seen splenomegaly in tumour-bearing animals,
specifically in the 4T1-model. Thus, differences in the ratio of red vs. white pulp in splenic
tissue needs to be studied further to determine whether this is an effect of prolonged 4T1
tumor growth or an effect of CTE.

Past studies have shown that the size of the primary tumour plays a key role in whether a
CTE or CTR effect is observed. For instance, Bruzzo et al., previously demonstrated
secondary tumour growth can be either stimulated or inhibited depending on the ratio
between the mass of the primary tumour relative to that of the secondary tumour implant.
They found that high ratios tended to cause inhibition of secondary tumour growth while
low ratios induced a stimulation effect8. For the present study, we injected our secondary
cancer cell line at an early time point (7 days post MFP injection) when the primary MFP
tumour is relatively small. We did this in an effort to best match the size of our MDA-MB231 model at the time of secondary injection. However, despite similar primary tumour
size at the time of secondary injection, these two models produced opposite effects
(CTE/CTR). This may be due to differences in cell line aggressiveness; 4T1 metastases
can be detected as early as 7 days whereas the less aggressive MDA-MB-231 model may
take between 2-3 weeks before metastases start to form in the brain. This is significantly
more time for the MDA-MB-231 primary tumour to grow (increasing the ratio between
primary and secondary) to produce a CTR effect on secondary tumour growth. In the 4T1
model, as metastases quickly develop, the ratio between primary and secondary tumours
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becomes smaller over time. In the current study, we also injected a second cohort of
animals at a late time point (14 days post MFP injection) when the primary tumour is
relatively large to try to increase the ratio between primary and secondary tumour
(producing a CTR effect). However, we found that increasing the size of the primary
tumour at the time of secondary injection significantly amplified our CTE effect.

An important step in the metastatic cascade is the initial arrest of cancer cells. When cancer
cells enter the circulation, they can travel through the bloodstream and arrest in the
capillary beds of distant sites throughout the body and extrasvasate into the interstitial
space where they can begin to form new tumours. For breast cancer patients, metastases
are most commonly found in the brain, bone, lung and liver25. Our multimodality imaging
tools allow us to noninvasively monitor both the number (MRI) and viability (BLI) of
arrested single cancer cells in the brain, allowing us to for the first time study the effect of
a primary tumour on cancer cell arrest as well as cancer cell clearance. In the present study,
we found there was not a significant difference in viable cancer cell arrest in the brain
between mice with a primary MFP tumour and control mice. We also found that there was
not a significant difference in cancer cell clearance from the brain, suggesting the presence
of a primary MFP tumour does not influence the number of viable, iron labeled cancer cells
that arrest in the brain at day 0, nor does it affect the clearance of these cells, indicating
that in this model the increased tumour growth we detected in mice with primary tumors
at endpoint is not due to effects at the early stages of the metastatic cascade. Another
important step is the intravasation of cells from the primary tumour. We will explore this

115

in the future by evaluating the effects of removal of the primary tumour on spontaneous
metastasis formation.

BLI was performed at endpoint on all mice to measure viable tumour burden in both the
brain as well as whole body. Although our MR analysis shows a strong CTE effect in the
brain of both the small and large MFP mice, we only found significant differences in brain
bioluminescence signal between mice with a large primary MFP tumour and control mice.
Previous studies have also shown disagreement in tumour volume and BLI measurements
at endpoint27,28. Although surprising, it should be noted that MRI and BLI are measuring
two different tumour characteristics; MRI is measuring tumour volume, which is affected
by many things including the number of tumour or stromal cells present and the presence
of edema, amongst other things, whereas BLI is providing a measure of the viability of the
engineered cancer cells over time. Moreover, BLI is not without its caveats, particularly
when studying metastatic disease. First, BLI signal is depth dependent. Small shallow
tumours will appear brighter or equivalent in signal to larger deep tumours. Hence, BLI
should be used for monitoring relative tumour viability over time rather than considering
BLI signal at any one-time point to represent a direct measure of absolute tumour burden.
Second, necrosis may be present within some of the metastases. While our MRI tumour
burden may be composed of both live and dead tumour tissue, BLI signal is representative
of viable cancer cells only. Third, any areas of hypoxia in a tumour may demonstrate lower
BLI signal due to the need for oxygen in the luciferase/luciferin reaction. Despite these
caveats, our previous work has shown that the information provided by both imaging
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modalities over time makes them very complementary technologies for studying cancer
metastasis18.

To account for the possibility of spontaneous metastases developing from our naïve
primary cell line and contributing to the main findings in this study, our metastatic cell line
was engineered to express GFP. As a result, we can confirm that any GFP-positive
metastases came from our intracardiac injection of metastatic cells, whereas GFP-negative
metastases are likely spontaneous metastases. In our endpoint histology, we did not find
any GFP-negative metastases (all 19 tumours found were GFP-positive), suggesting that
all brain metastases detected with MRI at endpoint came from our metastatic cell line and
not the primary tumour. In addition, we performed a study where we injected 300,000 4T1FLuc-GFP cells into the mammary fat pad of immune competent mice. We then monitored
primary tumour growth over 28 days with BLI. In this 4-week period we were not able to
detect distant metastases in the brain or any other organ. Since BLI is more sensitive than
MRI, we can be fairly confident that there are also not any MR-detectable metastases at
this time point. This has also been shown by other groups studying spontaneous metastasis
of 4T1 cells with BLI29. For example, Tao et al., shows that by week 6 after mammary fat
pad injection of 1x106 4T1 cells, only 1 of 6 mice had BLI-detectable metastases in the
brain. This is more than three times the number of cells that we are injecting for the current
study and thus, we do not expect spontaneous metastases to form in our 4-week time line.
In this study, we also show significant differences in endpoint tumour burden in the brain
with BLI measures. If a large portion of the MRI tumour burden was from spontaneous
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metastases, we predict we would not have seen the differences we found in our BLI
measurements.

3.5

Conclusion

In this work, we applied cellular and molecular imaging tools to evaluate the effect of a
primary breast tumour and its size on the growth of brain metastases in the immune
competent 4T1 mouse model. We found total brain tumour burden was significantly greater
in mice with a primary MFP tumour (Small or Large) compared to those without. We also
found that mice with a large MFP tumour had significantly more BLI signal in the brain at
endpoint compared to control mice. Interestingly, using in vivo BLI and MRI we could
determine that these differences in endpoint tumour burden were not related to differences
in the initial arrest or clearance of viable cells in the brain, which suggests that the presence
of a primary tumour can increase the proliferative growth of brain metastases in this
syngeneic 4T1 mouse model. Future work will utilize our imaging tools to explore the role
of the immune system in promoting or preventing metastatic growth. Understanding the
different immunological and/or molecular mechanisms of stimulation (CTE) versus
inhibition (CTR) will be extremely valuable in finding new therapeutic options for breast
cancer patients.

118

3.6
1.

References
Siegel, R., Ma, J., Zou, Z., Jemal, A. CA: a cancer journal for clinicians. Cancer
Statistics. 64, (1):9-29 (2014).

2.

Scully, O.J., Bay, B.H., Yip, G., Yu, Y.Breast cancer metastasis. Cancer Genomics
Proteomics. 9, (5):311-320 (2012).

3.

Chiarella, P., Bruzzo, J., Meiss, R.P., Ruggiero, R.A. Concomitant tumor
resistance. Cancer Lett. 28, 324(2): 133-41 (2012).

4.

Prehn, R.T. The inhibition of tumor growth by tumor mass. Cancer Res. 51, 2-4
(1991).

5.

Demicheli, R., Miceli, R., Moliterni, A., Zambetti, M., Hrushesky, W.J., Retzky,
M.W., et al. Breast cancer recurrence dynamics following adjuvant CMF is
consistent with tumour dormancy and mastectomy-driven acceleration of the
metastatic process. Ann Oncol . 16, 1449-1457 (2005).

6.

McAllister, S.S., Gifford, A.M., Greiner, A.L., Kelleher, S.P., Saelzler, M.P., Ince,
T.A., et al. Systemic endocrine instigation of indolent tumor growth requires
osteopontin. Cell. 133, 994-1005 (2008).

7.

Janik, P., Bertram, J.S., Szaniawska, B. Modulation of lung tumor colony formation
by a subcutaneously growing tumor. J Natl Cancer Inst. 66, 1155-8 (1981).

8.

Bruzzo, J., Chiarella, P., Meiss, R.P., Ruggiero, R.A. Biphasic effect of a primary
tumour on the growth of secondary tumour implants. J Cancer Res Clin Oncol. 136,
1605-15 (2010).

119

9.

Vizel, M.W., Oster, J.H., Austin. Spontaneous regression of a pulmonary
metastasis after nephrectomy for renal cell carcinoma. J. Surg. Oncol. 12, 175–180
(1979).

10.

Lokick, J. Spontaneous regression of metastatic renal cancer: Case report and
literature review. Am. J. Clin. Oncol. 20, 416–418 (1997).

11.

Wyczolkowski, M., Klima, W., Bieda, W., Walask, K. Spontaneous regression of
hepatic metastases after nephrectomy and mastectomy of renal cell carcinoma.
Urol. Int. 66, 119–120 (2001).

12.

Lekanidi, K., Vlachou, P.A., Morgan, B., Vasanthan, S. Spontaneous regression of
metastatic renal cell carcinoma: case report. J. Med. Case Reports. 1, 89 (2007).

13.

El Saghir, N. S., Elhajj, I. I., Geara, F. B., & Hourani, M. H. Trauma-associated
growth of suspected dormant micrometastasis. BMC cancer. 5(1), 94 (2005).

14.

Kirstein, J. M., Hague, M. N., McGowan, P. M., Tuck, A. B., & Chambers, A. F.
Primary melanoma tumor inhibits metastasis through alterations in systemic
hemostasis. Journal of Molecular Medicine. 94(8), 899-910 (2016).

15.

Franco, M., Bustuoabad, O. D., Di Gianni, P. D., Goldman, A., Pasqualini, C. D.,
& Ruggiero, R. A. A serum-mediated mechanism for concomitant resistance shared
by immunogenic and non-immunogenic murine tumours. British journal of cancer.
74(2), 178 (1996).

16.

Hamilton, A.M., Parkins, K.M., Murrell, D.H., Ronald, J.A., Foster, P.J.
Investigating the Impact of a Primary Tumor on Metastasis and Dormancy Using
MRI: New Insights into the Mechanism of Concomitant Tumor Resistance.
Tomography. 2 (2), 79-84 (2016).

120

17.

Shapiro, E.M., Skrtic, S., Sharer, K., Hill, J.M., Dunbar, C.E., Koretsky, A.P. MRI
detection of single particles for cellular imaging, Proc Natl Acad Sci USA. 101,
10901- 10906 (2004).

18.

Parkins, K. M., Hamilton, A. M., Makela, A. V., Chen, Y., Foster, P. J., & Ronald,
J. A. A multimodality imaging model to track viable breast cancer cells from single
arrest to metastasis in the mouse brain. Sci. Rep. 6, 35889 (2016)

19.

McFadden, C., Mallett, C.L., Foster, P.J. Labeling of multiple cell lines using a new
iron oxide agent for cell tracking by MRI. Contrast Media Mol Imaging. 6(6), 514–
522 (2011).

20.

Euhus, D.M., Hudd, C., LaRegina, M.C., Johnson, F.E. Tumor measurement in the
nude mouse. J Surg Oncol. 31, 229-234 (1986).

21.

Tomayko, M.M., Reynolds, C.P. Determination of subcutaneous tumor size in
athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148-154 (1989).

22.

Heyn, C., Bowen, C., Rutt, B. & Foster, P. Detection threshold of single SPIOlabeled cells
with FIESTA. Magnet Reson Med. 53, 312-320 (2005).

23.

Heyn, C. et al. In vivo MRI of cancer cell fate at the single-cell level in a mouse
model of breast cancer metastasis to the brain. Magn Reson Med. 56, 1001-1010
(2006).

24.

Ribot, E. et al. In vivo single scan detection of both iron-labeled cells and breast
cancer
metastases in the mouse brain using balanced steady-state free precession imaging
at 1.5 T. J. Magn Reson Imaging.34, 231-238 (2011).

121

25.

Parker, B., Sukumar, S. Distant metastasis in breast cancer: molecular mechanisms
and therapeutic targets. Cancer Biol Ther. 2,14–21 (2003).

26.

Vaage, Y. Free tumor antigen and immune serum factors in control of metastasis.
Gan Monogr Cancer Res. 20, 129-145 (1977).

27.

Song, H.T., Jordan, E.K., Lewis, B.K., Liu, W., Ganjei, J., Klaunberg, Frank, J.A.
Rat model of metastatic breast cancer monitored by MRI at 3 tesla and
bioluminescence imaging with histological correlation. Journal of translational
medicine. 7(1), 88 (2009).

28.

Black, P.C., Shetty, A., Brown, G.A., Esparza‐Coss, E., Metwalli, A.R., Agarwal,
P.K., Dinney, C.P. Validating bladder cancer xenograft bioluminescence with
magnetic resonance imaging: the significance of hypoxia and necrosis. BJU
international. 106(11), 1799-1804 (2010).

29.

Tao, K., Fang, M., Alroy, J., Sahagian, G.G. Imagable 4T1 model for the study of
late stage breast cancer. BMC cancer. 8(1), 228 (2008).

122

Chapter 4

4
Engineered self-homing circulating tumour cells as novel
metastatic breast cancer theranostics
Purpose: New ways to target and treat metastatic disease are urgently needed. Tumor
“self-homing” describes the recruitment of circulating tumor cells (CTCs) back to a
previously excised primary tumor location, contributing to tumor recurrence, as well as
their migration to established metastatic lesions. Recently, self-homing CTCs have been
exploited as delivery vehicles for anti-cancer therapeutics in preclinical primary tumor
models. However, the ability of CTCs to self-home and treat metastatic disease is largely
unknown. Methods: Here, we employ molecular imaging to explore whether systemicallyadministered CTCs home to metastatic lesions and if CTCs armed with both a reporter
gene and a cytotoxic prodrug gene therapy can be used to visualize and treat metastatic
disease. Results: Bioluminescence imaging (BLI) performed over time revealed a
remarkable ability of CTCs to home to primary and metastatic tumors throughout the body.
Mice that received therapeutic CTCs had less BLI signal as well as less primary tumour
burden than control mice. Preliminary data also showed self-homing therapeutic CTCs may
be effective at treating disseminated breast cancer metastases. Conclusion: Using dualluciferase BLI, this study demonstrates the noteworthy ability of experimental CTCs to
home to disseminated breast cancer lesions. Moreover, by incorporating a prodrug gene
therapy system into our self-homing CTCs, we show exciting progress towards effective
and targeted delivery of gene-based therapeutics to treat both primary and metastatic
lesions.
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4.1

Introduction

Cancer patient outcomes have significantly improved in the last few decades due to
superior cancer imaging, surgical, and radiotherapy techniques, the recent application of
‘omics’ lesion profiling to guide therapy, and more efficacious drugs [1]. These advances
now allow many patients with localized primary tumours or minimal metastatic disease at
the time of diagnosis, or during recurrence, to be effectively managed. Yet despite these
transformative advances, the ability to benefit patients with highly disseminated metastatic
disease remains a significant challenge. Difficulties with controlling metastatic disease
include, but are not limited to, the lack of tools to visualize lesions at an earlier stage when
they may be more readily treated, insufficient systemic delivery of therapeutics to all
lesions, and, most notably, extensive tumour heterogeneity both within and between lesions
throughout the body [2,3]. These substantial barriers highlight an unmet need for new
technologies to effectively visualize and treat metastatic lesions, preferably so-called
theranostic tools that have both diagnostic and therapeutic capabilities.

Cells are an attractive form of theranostic vector as they can be readily engineered ex vivo
prior to transplantation with both molecular-genetic imaging reporter genes for
noninvasive localization and therapeutic transgenes [4-7]. While some cell types have been
shown to naturally home to lesions, such as stem cells and immune cells [8-14], one can
also engineer cells with receptors targeting tumour-associated antigens to redirect in vivo
cellular tropism. Recently, chimeric antigen receptor T cells (CAR-T cells) targeting the B
cell antigen CD-19 became the first genetically-modified cell-based therapies to be
approved for patients with relapsed or refractory B-cell precursor acute lymphoblastic
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leukemia and large B cell lymphoma [15-18]. While substantial efforts are now aimed at
using CAR-T cells for the treatment of solid tumours, so far, their less than ideal therapeutic
effectiveness has been attributed to insufficient tumour-homing and/or intratumoural
immunological barriers [19]. Thus, the continued exploration of alternative cell types that
can effectively home to metastatic solid tumours for use as novel theranostic vectors is
warranted.

Paget’s “seed and soil hypothesis” describes the wide dissemination of “seeds”, or
circulating tumour cells (CTCs), from a primary tumour and the formation of overt
metastases selectively in “soils” that permit CTC survival and proliferation [20]. However,
due to the non-permissive nature of tumour-free organs, metastasis has been shown to be
an inefficient process in both experimental animal models and cancer patients [21-23]. The
impedance of the formation of new metastases has been partly attributed to both vascular
barriers that inhibit CTC extravasation from the blood as well as unfavorable survival
conditions [24]. Conversely, shed CTCs have been shown to be highly capable of homing
back to their tumour of origin, a concept termed tumour “self-seeding” that was first
suggested and demonstrated by Kim and colleagues [25]. Self-seeding has been shown in
animal models of human breast, colon and melanoma cancer, and is theorized to contribute
to tumour recurrence following resection [25]. Unlike in tumour-free organs, tumour
vasculature is often “leaky” due to a compromised vascular endothelium, and thus, more
easily facilitates the extravasation of CTCs back into their original tumours [26]. Moreover,
the primary tumour microenvironment is considered highly permissive soil for the
continued survival and growth of recruited CTCs, leading to the expansion of highly
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metastatic clones that have a higher capacity to seed distant organs [25]. Similarly,
metastatic lesions that have formed in distant organs are also considered fertile soil for
additional “self-homing” CTCs to migrate to, survive, and expand within, which may
contribute to accelerated metastatic disease progression [25].

In the last two decades, several groups have exploited self-homing CTCs as “self-targeted”
delivery vehicles for ex vivo loaded anti-cancer therapeutic cargo [27-32]. Cargo has
included oncolytic viruses such as the H-1 parvovirus and vesicular stomatitis virus (VSV),
prodrug converting enzyme genes including herpes simplex virus thymidine kinase (HSVTK) and cytosine deaminase (CD), transgenes that target the tumour microenvironment
such as tumour necrosis factor (TNF), and the secretory version of TNF-related apoptosisinducing ligand (S-TRAIL). Additionally, a few groups have co-engineered the therapeutic
CTCs and/or their viral cargo with optical or positron emission tomography (PET) imaging
reporter genes to enable the fate of the cells/cargo to be monitored with molecular-genetic
imaging [28-30, 32]. Importantly, while the ability to target, visualize, and treat singular
pre-established subcutaneous tumours as well as orthotopic or metastatic lesions in a
singular organ (e.g., lungs [28] or brain [32]) has been demonstrated, to the best of our
knowledge, the ability of self-homing CTCs to migrate into and be used to visualize and
treat spontaneous multi-organ metastatic disease is largely unknown.

Here, we employed longitudinal molecular-genetic imaging to show that systemicallyadministered engineered CTCs efficiently home to both orthotopic and spontaneous
metastatic breast cancer lesions. Further, we demonstrate that CTCs armed with both an

126

imaging reporter gene and the gene for the prodrug converting enzyme cytosine deaminaseuracil phosphoribosyltransferase (CD:UPRT) can be used to effectively visualize and treat
metastatic disease, resulting in distinctly increased survival times. Our preclinical study
supports engineered CTCs as a novel self-targeting cellular theranostic platform for the
visualization and treatment of distributed metastases - the most relevant lesions to patient
outcome.

4.2 Results
4.2.1 Tracking of Self-Homing Cancer Cells in a Contralateral
Orthotopic Tumour Model
Previous studies have shown that breast cancer cells from one mammary fat pad can home
into a contralateral mammary fat pad (MFP) tumour [25]. Thus, we first started exploring
the use of imaging to monitor tumour self-homing using this same experimental setup. We
engineered the mouse breast cancer cell line (4T1) and its brain-seeking metastatic variant
(4T1BR5) to express the orthogonal bioluminescence imaging (BLI) reporters Renilla
luciferase (RLuc) and Firefly luciferase (FLuc), respectively.

This allowed us to

sensitively track both populations in the same animal over time. 4T1 cells were transduced
with a lentiviral vector encoding both RLuc and ZsGreen and sorted to obtain 4T1-RLuc
cells (Suppl. 4.1A). No significant change in ZsGreen expression over multiple passages
was seen (Suppl. 4.1B) and there was a significant positive correlation shown between the
number of 4T1-RLuc cells and RLuc/ZsGreen signal (R2 = 0.99, p<0.001; Suppl. 4.1C).
FLuc-expressing 4T1BR5 (4T1BR5-FLuc) cells were engineered and characterized
similarly in a previous study [33]. We next ensured a lack of cross-reactivity of the
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luciferase substrates. 4T1BR5-FLuc cells incubated with D-luciferin demonstrated
significantly higher BLI signal than 4T1-RLuc cells, 4T1 parental cells, or equivalent
volume of media, and 4T1-RLuc cells did not produce signal significantly different than
4T1 parental cells or media alone (p<0.001; Suppl. 4.1D). Similarly, after the addition of
h-Coelenterazine, 4T1-RLuc cells had significantly higher signal than 4T1BR5-FLuc cells,
4T1 parental cells, or equivalent volume of media and 4T1BR5-FLuc cells did not produce
signal significantly different than 4T1 parental cells or media alone (p<0.001; Suppl. 4.1E).
We next explored the migration of our engineered cells towards conditioned media from
both cell lines using transwell migration assays. A significant increase in cell migration
was seen for 4T1BR5-FLuc cells when conditioned media from 4T1-RLuc cells was used
compared to conditioned media from 4T1BR5-FLuc cells or unconditioned media (p<0.01;
Suppl. 4.1F). A significant increase in cell migration was also seen for 4T1-RLuc cells
when conditioned media from 4T1-RLuc cells was used compared to unconditioned media
(p<0.01; Suppl. 4.1F).

4T1-RLuc cells were then implanted into the right MFP of nude mice (n=5) and 4T1BR5FLuc cells were implanted into the contralateral (left) MFP (Figure 4.1A). This allowed us
to validate the lack of substrate cross-reactivity in vivo at early time points after cell
injection (Days 0 and 1; Figures 4.1 and Suppl. 4.2) as well as the ability to evaluate
whether either of the cell lines migrated into the contralateral MFP tumour (Figure 4.1).
On Day 0 after cell injection, 4T1-RLuc cells only showed signal after administration with
h-coelenterazine and on Day 1, 4T1BR5-FLuc cells only showed signal after
administration of D-Luciferin (Suppl. 4.2). By day 7, 4T1BR5-FLuc cells did not appear

128

to migrate as FLuc signal was not detected in the contralateral MFP (Figure 4.1D). In
contrast, 4T1-RLuc cells could be detected in the contralateral MFP tumour, and RLuc
signal was significantly higher in the contralateral compared to ipsilateral MFP (Figure
4.1C). The presence of both 4T1-RLuc and 4T1BR5-FLuc cells in the left MFP was
confirmed histologically (Figure 4.1E, 4.1F), supporting our non-invasive imaging results
and validating that the 4T1-RLuc cells left their initial site of implantation and homed to
the contralateral MFP tumour.
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Figure 4.1 Experimental timeline for contralateral tumour self-homing model
(n=5): On Day 0 after cell injection, 4T1-RLuc cells only showed signal after
administration with h-coelenterazine and on Day 1, 4T1BR5-FLuc cells only
showed signal after administration of D-Luciferin. By day 7, 4T1BR5-FLuc
cells did not appear to migrate as FLuc signal was not detected in the
contralateral MFP but 4T1-RLuc cells could be detected in the contralateral
MFP tumour (B). RLuc signal on day 7 was significantly higher in the
contralateral MFP compared to the ipsilateral MFP on day 8 (C/D). The
presence of both 4T1-RLuc and 4T1BR5-FLuc cells in the left MFP was
confirmed histologically (scale bars= 500 microns) (E/F).
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4.2.2 Monitoring Self-Targeted Therapy in a Contralateral
Orthotopic Tumour Model
We next evaluated the ability of self-homing 4T1-RLuc cells expressing the therapeutic
prodrug converting fusion enzyme cytosine deaminase-uracil phosphoribosyltransferase
(CD:UPRT) to treat contralateral MFP tumours. CD:UPRT converts non-toxic 5’fluorocytosine (5’FC) into the cytotoxic compound 5’fluoruridine monophosphate
(5’FUMP) and was chosen as a suicide switch to eliminate the therapeutic cells as well as
a way to kill adjacent non-engineered cancer cells via the bystander effect [34-37]. 4T1RLuc and 4T1BR5-FLuc cells were transduced with a lentiviral vector co-expressing
CD:UPRT (CD for brevity) and tdTomato (tdT), and sorted via tdT to obtain 4T1-RLuc/CD
(4T1-CD) cells and 4T1BR5-FLuc/CD (4T1BR5-CD) cells (Figures 4.2A and Suppl.
4.3A). After 96 hours of incubation with 5’FC (5mM), CD expressing cells showed
significantly less survival than cells without drug as well as significantly less survival than
4T1-RLuc and 4T1BR5-FLuc cells with or without drug (Figures 4.2B and Suppl. 4.3B).
At all doses (0.005mM, 0.05mM, 0.5mM, 5mM), CD expressing cells show significantly
less survival than cells without drug (Figures 4.2C and Suppl. 4.3C).
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Figure 4.2 Therapeutic cell characterization: 4T1-RLuc cells were transduced with a
lentiviral vector co-expressing the therapeutic prodrug converting fusion enzyme
cytosine deaminase-uracil phosphoribosyltransferase (CD:UPRT) and tdTomato
(tdT), and sorted via tdT to obtain 4T1-RLuc/CD cells (A). After 96 hours of
incubation with 5’FC (5mM), CD expressing cells showed significantly less survival
than cells without drug as well as significantly less survival than 4T1-RLuc cells with
or without drug (B). At all doses, CD expressing cells show significantly less survival
than cells without drug (C).
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Next, we performed in vivo experiments whereby either 4T1-RLuc (n=4) or 4T1-CD (n=4)
cells were implanted into the right MFP and 4T1BR5-FLuc into the contralateral MFP. All
mice were treated with 5’FC daily from days 8 to 14 (Figure 4.3A). As visualized with
RLuc BLI, on day 7 before treatment, both 4T1-CD and 4T1-RLuc cells can be seen in the
contralateral MFP tumour and RLuc signal at this site was not significantly different
between mouse cohorts (Figure 4.3B, 4.3C). At day 14 following treatment, FLuc BLI
signal was observed in both contralateral and ipsilateral MFPs and signal was not
significantly different between the two mouse groups in both MFPs (Figure 4.3E, 4.3F).
At endpoint, areas of necrosis were evident in MFP tumours from both mouse cohorts using
hematoxylin and eosin (H&E) staining (Figure 4.3G).
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Figure 4.3 Experimental timeline for contralateral tumour treatment (n=8): All mice
were treated with 5’FC daily from days 8 to 14. As visualized with RLuc BLI, on day
7 before treatment, both 4T1-RLuc/CD and 4T1-RLuc cells can be seen in the
contralateral MFP tumour and RLuc signal at this site was not significantly different
between mouse cohorts (B/C). tDT expressing therapeutic cells were visualized in the
contralateral MFP using fluorescence microscopy at day 7 before drug
administration (scale bars=200 microns). At day 14 following treatment, FLuc BLI
signal was observed in both contralateral and ipsilateral MFPs and signal was not
significantly different between the two mouse groups (E/F). At endpoint, areas of
necrosis were evident in MFP tumours from both mouse cohorts using hematoxylin
and eosin (H&E) staining (black scale bars= 1mm; white scale bars= 20 microns) (G).
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4.2.3 Intratumoural Injection of Therapeutic Cancer Cells Can
Treat Orthotopic Tumours
We hypothesized the lack of therapeutic effect in the previous experiment may have been
due to insufficient numbers of 4T1-CD cells migrating into the contralateral MFP tumour.
Immunostaining of mice sacrificed on day 7 confirmed the presence of both 4T1BR5-FLuc
and 4T1-CD cells in the left MFP, but a relatively low ratio of 4T1-CD to 4T1BR5-FLuc
cells was noted (Figure 4.3D). To further test our hypothesis, we allowed the 4T1BR5FLuc tumours to grow for 7 days prior to injecting 3x105 4T1-RLuc or 4T1-CD cells
intratumourally and treated all mice with 5’FC daily from days 8 to 16 (Figure 4.4). 4T1
cells were visualized with RLuc BLI on days 7 and 15, and 4T1BR5 cells with FLuc BLI
on days 0, 4, 8 and 16 (Figure 4.4A). Importantly, RLuc BLI of mice intratumourally
injected with 4T1-CD cells was significantly higher than in mice that had the same cells
home from the contralateral MFP the day prior to treatment initiation (Figure 4.4B, 4.4C).
At day 15 after treatment, mice that received 4T1-CD cells intratumourally had a larger
percent signal loss of RLuc signal compared to mice that received 4T1-RLuc cells,
indicating the ability to mitigate therapeutic cancer cell growth via suicide switch
activation (Figure 4.4B, 4.4D). Furthermore, by day 16, mice that received 4T1-CD cells
had significantly less FLuc signal compared to mice that received 4T1-RLuc cells,
indicating kill of adjacent cells via the bystander effect (Figure 4.4E, 4.4F). Measuring
FLuc signal by BLI was complicated by the development of tumour ulcerations in both
groups, which partially blocked signal. Large areas of necrosis were seen in histological
sections of MFP tumours from both mouse cohorts (Figure 4.4G). Therefore, we also
assessed treatment response by measuring MFP tumour volumes over time with calipers.
Mice that received 4T1-CD cancer cells had significantly smaller tumour volumes than
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control mice at both days 14 and 17 (Figure 4.4H, 4.4I). Of the 4 control mice, 3 had to be
sacrificed prior to the day 21 due to predetermined endpoints, either the size of the tumour
(> 2cm3) and/or the presence of excessive ulceration. As a result, 5’FC treated mice that
received 4T1-RLuc/CD cells showed significantly improved survival times compared to
mice receiving 4T1-RLuc cells (p<0.01; Figure 4.4J).
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Figure 4.4 Experimental timeline for intratumoural injection of therapeutic cancer
cells (n=8): All mice were treated with 5’FC daily from days 8 to 16. 4T1-Rluc and
4T1-RLuc/CD cells were visualized in the left MFP with BLI on days 7 and 15 (B)
RLuc BLI of mice intratumourally injected with 4T1-RLuc/CD cells was significantly
higher than in mice that had the same cells home from the contralateral MFP the day
prior to treatment initiation (C). Mice that received 4T1-RLuc/CD cells
intratumourally had a larger percent signal loss of RLuc signal compared to mice that
received 4T1-RLuc cells, indicating the ability to mitigate therapeutic cancer cell
growth via suicide switch activation (D). Furthermore, by day 16, mice that received
4T1-RLuc/CD cells had significantly less FLuc signal compared to mice that received
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4T1-RLuc cells, indicating kill of adjacent cells via the bystander effect (E/F). At
endpoint, areas of necrosis were evident in MFP tumours from both mouse cohorts
using hematoxylin and eosin (H&E) staining (black scale bars= 1mm; white scale
bars= 20 microns) (G). Treatment response was also assessed by measuring MFP
tumour volumes over time with calipers. Mice that received 4T1-RLuc/CD cancer
cells had significantly smaller tumour volumes than control mice at both days 14 and
17 (H/I). 5’FC treated mice that received 4T1-RLuc/CD cells showed significantly
improved survival times compared to mice receiving 4T1-RLuc cells (J).

138

4.2.4 Primary Tumours and Spontaneous Metastases can be
Visualized with Systemically-Administered “Diagnostic” CTCs
We next assessed the ability of systemically-administered CTCs to home to primary
tumours and spontaneous metastases. We implanted 4T1-RLuc cells into the right MFP of
nude mice (n=5) and allowed tumours to grow for 7 days prior to injecting 4T1BR5-FLuc
CTCs via an intracardiac injection under ultrasound guidance (Figure 4.5A). RLuc BLI
was performed on days 0, 6, 13 and 19 to visualize cells in the right MFP and any
spontaneous metastases and FLuc BLI was performed on days 7, 14 and 20 to visualize
CTCs (Figure 4.5A, 4.5B). RLuc BLI showed the presence of metastases in 1 of 5 mice on
day 6 prior to CTC injection. RLuc tumours were often found in the brain and/or hind
limbs. FLuc BLI over time revealed the ability of FLuc-expressing CTCs to home to RLucexpressing primary tumours and spontaneous metastases throughout the body (Figure
4.5B). Quantitative analysis of endpoint BLI images (day 19 and 20) revealed that the vast
majority of metastases were composed of both 4T1-RLuc and 4T1BR5-FLuc cells
(M=9.81.9), which was significantly higher than the number of metastases that were
either 4T1-RLuc-positive only (M=0.60.4; p<0.01) or 4T1BR5-FLuc-positive only
(M=0.20.2; p<0.001) (Figures 4.5C, 4.5D, Suppl. 4.4). The presence of both 4T1-RLuc
and 4T1BR5-FLuc cells in numerous metastases was confirmed histologically (Figures
4.5E, Suppl. 4.4B), supporting our non-invasive imaging results.
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Figure 4.5 Experimental timeline for visualizing diagnostic CTCs (n=5): RLuc BLI
was performed on days 0, 6, 13 and 19 to visualize cells in the right MFP and any
spontaneous metastases and FLuc BLI was performed on days 7, 14 and 20 to
visualize CTCs (B). FLuc-expressing CTCs efficiently homed to RLuc-expressing
primary tumours and spontaneous metastases throughout the body (C). Quantitative
analysis of endpoint BLI images (day 19 and 20) revealed that the vast majority of
metastases were composed of both 4T1-RLuc and 4T1BR5-FLuc cells, which was
significantly higher than the number of metastases that were either 4T1-RLucpositive only or 4T1BR5-FLuc-positive only (p< 0.001) (C/D). The presence of both
4T1-RLuc and 4T1BR5-FLuc cells in metastases was confirmed histologically (scale
bars= 500 microns) (E).
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4.2.5 Self-Homing “Theranostic” CTCs Efficiently Migrate into
and Treat Primary Tumours and Spontaneous Metastases
Finally, we investigated whether theranostic CTCs could be systemically administered to
treat primary and disseminated lesions. Again, 4T1-RLuc cells were implanted into the
right MFP of nude mice and allowed 7 days of tumour growth prior to intracardiac injection
of either 4T1BR5-CD cells (n=6) or 4T1BR5-FLuc cells (n=6). These mice were treated
with 5’FC daily from days 10 to 20. We also included an additional cohort of mice (n=4)
who received an MFP injection of 4T1-RLuc cells only and were not administered 5’FC
(“4T1 Only mice” in Figure 4.6). In our first cohort (n=4), all mice had primary tumour
growth similar to our data with our “diagnostic” CTCs and also developed sufficient
metastases to assess therapeutic effects on metastases (Figure 4.7). In our second cohort,
12/12 mice had MFP tumours that did not develop as well as in previous cohorts at the time
of secondary injection and thus, did not develop more than one or two metastases per mouse
by endpoint. For these mice, we only assessed the effects of treatment on primary tumour
growth (Figure 4.6). RLuc BLI was performed on days 0, 6, 13 and 19 to visualize cells in
the right MFP and any spontaneous metastases and FLuc BLI was performed on days 7,
14 and 20 to visualize CTCs (Fig. 6A). As visualized by RLuc BLI, by day 6 (prior to drug
administration), mice receiving 4T1BR5-CD cells had MFP RLuc signal that was not
significantly different than mice receiving 4T1BR5-FLuc cells or mice receiving 4T1 cells
only (Figure 4.6B, 4.6C). However, by day 19, mice receiving 4T1 cells only, had a
significantly higher percent increase of RLuc signal in the MFP compared to mice that
received 4T1BR5-CD cells (Figure 4.6B, 4.6D). At endpoint, primary tumours were not
palpable in mice that received 4T1BR5-CD expressing cells (Figure 4.6E, 4.6F). These
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data support the notion that systemically administered “theranostic” CTCs are capable of
returning to and effectively treating the primary tumour. Of the 6 mice that received
4T1BR5-FLuc cells, 2 had to be sacrificed prior to endpoint due to both the size of the
tumours and presence of ulceration. Overall, mice that received 4T1BR5-CD cells showed
significantly improved survival compared to mice receiving 4T1BR5-FLuc cells and mice
receiving 4T1 cells only (p<0.01; Figure 4.6G). In the 4 mice that developed notable
metastases, mice receiving 4T1BR5-CD CTCs (n=2) and 4T1BR5-FLuc CTCs (n=2) had
near equivalent FLuc signal on the day of CTC injection, but by day 14, mice receiving
4T1BR5-CD CTCs had visibly less FLuc signal (Figure 4.7B, 4.7C). Both mice that
received 4T1BR5-FLuc cells had to be sacrificed prior to endpoint due to both the size of
primary tumours and presence of ulceration, and thus, FLuc imaging on days 20 and 29
was only performed on mice that received 4T1BR5-CD cells. Importantly, mice in each
cohort had similar RLuc signal on days 0 and 6 prior to CTC administration (Figure 4.7D,
4.7E), but by day 19, the single mouse that received 4T1BR5-FLuc cells and survived until
day 19, had visibly more RLuc metastases than both mice that received 4T1BR5-CD cells
(Figure 4.7D, 4.7E).
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Figure 4.6 Experimental timeline for visualizing self-homing theranostic CTCs
(n=16): 4T1BR5-CD and 4T1BR5 mice were treated with 5’FC daily from days 10 to
20. RLuc BLI was performed on days 0, 6, 13 and 19 to visualize cells in the right
MFP and FLuc BLI was performed on days 7, 14 and 20 to visualize CTCs (B/E). By
day 6 (prior to drug administration), mice receiving 4T1BR5-CD cells had MFP RLuc
signal that was not significantly different than mice receiving 4T1BR5 cells or 4T1
cells only (C). However, by day 19, mice receiving only 4T1-RLuc cells had a
significantly higher percent increase of RLuc signal in the MFP compared to mice
that received 4T1BR5-CD cells (D). At endpoint, primary tumours were not palpable
in mice that received 4T1BR5-CD cells (F). These data support the notion that
systemically administered “theranostic” CTCs are capable of returning to and
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effectively treating the primary tumour (E). Mice that received 4T1BR5-CD cells
showed significantly improved survival compared to mice receiving 4T1BR5 cells and
mice receiving 4T1 cells only (G).
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Figure 4.7 Treating metastases: On the day of intracardiac injection (day 7), mice
receiving 4T1BR5-CD CTCs (n=2) and 4T1BR5 CTCs (n=2) had near equivalent
FLuc signal (A/B), but by day 14, mice receiving 4T1BR5-CD CTCs had visibly less
FLuc signal (C/D). Both mice that received 4T1BR5 cells had to be sacrificed prior to
endpoint due to both the size of primary tumours and presence of ulceration, and
thus, FLuc imaging on days 20 and 29 was only performed on mice that received
4T1BR5-CD cells. Importantly, mice in each cohort had similar RLuc signal on days
0 and 6 prior to CTC administration (E/F), but by day 19, the single mouse that
received 4T1BR5 cells and survived until day 19, had visibly more RLuc metastases
than both mice that received 4T1BR5-CD cells (G/H).
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4.3

Discussion

This study demonstrates that engineered “self-homing” CTCs co-expressing an imaging
reporter and a therapeutic transgene can be used as a novel theranostic cellular vector to
visualize and treat both primary tumours and disseminated spontaneous breast cancer
metastases in mice. We first show using dual-luciferase BLI the remarkable ability of
systemically-administered CTCs to preferentially home to pre-established spontaneous
metastases in various organs throughout the body with minimal formation of new tumours.
Leveraging on this highly preferential homing capability, we then show that CTCs coexpressing the prodrug converting fusion enzyme system CD:UPRT, to kill neighboring
cells via the bystander effect as well as act as a suicide switch, was able to decrease tumour
burden and extend survival.

Cancer, particularly in patients with metastatic disease, remains a leading cause of death in
the world [38, 39]. Treatments that often work on localized disease are often not an option
or fail in the patients with significant metastatic spread. Thus, the development of
technologies for earlier detection and treatment of metastatic disease remains at the
forefront of cancer research. Therapeutics that have natural tumour tropism or are designed
to target lesions offer potential benefits of improved therapeutic effectiveness due to high
intratumoural concentration of therapeutic payloads, as well as increased safety due to
minimization of off-target cytotoxicity in normal tissues [4-19, 27-32]. The incorporation
of imaging probes (e.g., radiolabels, iron oxides, etc.) into these targeted agents has been
used to allow one to track their whole-body biodistribution to on-tumour and off-tumour
sites [28-30, 32]. An agent that is very effective at naturally localizing to metastases with
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little off-target accumulation could theoretically also be used as an effective agent for the
early diagnosis and treatment of metastatic disease.

In recent years, numerous classes of tumour-targeting agents have been developed
including small molecules [40], antibodies [41-43], nanoparticles [44, 45], viral [46-48] and
non-viral gene vectors [49-51], and cell-based vectors [4-19, 27-32]. Traditionally, the
development of cell-based therapies has focused on the use of stem-cells including tissuespecific stem cells, pluripotent stem cells or mesenchymal stem cells [5,6,8-14]. These
approaches offer many important benefits including their innate homing capabilities and
natural anti-tumour effects; however, they suffer from limited passaging in culture
resulting in roadblocks throughout the engineering process as well as limited therapeutic
potential in vivo. Similarly, others have used immune cell-based vectors in efforts to target
and treat a variety of tumours including tumour-infiltrating lymphocytes (TILs) [52, 53]
and cytokine induced killer (CIK) cells [54, 55]. CIK cells are a group of immune effector
cells with a mixed T- and natural killer (NK) cell phenotype. Thorne and colleagues
successfully showed this effector cell population could be loaded with an oncolytic virus
for targeted delivery and treatment of murine tumours [55]. Currently, one of the most
employed cell-based tumour-targeting strategies is the engineering of T lymphocytes with
chimeric antigen receptors (CARs) in efforts to selectively recognize and kill cancer cells
expressing the B cell antigen CD19, while sparing healthy tissue [15-18]. This strategy has
shown tremendous promise in the clinic in upwards of 70% of patients with otherwise
treatment-refractory B cell leukemia and other B cell malignancies such as diffuse large Bcell lymphoma. However, in some cases, CAR-T cell therapy has shown no effect at all,
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and in many cases, patients experience potentially lethal side effects as a result of CAR-T
cells not proliferating and persisting in the body over time, proliferating and activating
excessively, or nonspecific homing to healthy organs [19, 56]. CAR-T cells have also
shown minimal therapeutic effectiveness for solid tumours due to less than ideal homing
capacity. Thus, there remains a need for novel cell-based delivery vehicles that are capable
of homing to solid tumours.

In 2009, Kim and colleagues demonstrated the ability of cancer cells from an established
lesion to enter the circulation and then return to this lesion to continue to survive and
proliferate, a process they termed “self-seeding” [25]. The self-seeding capabilities of
cancer cells was attributed to both the recruitment potential of the established tumour
microenvironment as well as the seeding capabilities of cancer cells themselves. As a
result, several groups have attempted to repurpose the self-homing properties of cancer
cells to use them as “self-targeted” cell-based delivery vehicles for anti-cancer therapeutics
[27-32]. In comparison to previously discussed cell-based vectors (i.e., stem cells and
immune cells), cancer cells can be continuously grown in vitro enabling extensive cell
engineering, may have superior homing capability to lesions, and may have prolonged
survival and expansion once in tumours. Past studies have included using cancer cells as a
vehicle to deliver oncolytic viruses [27, 28], engineering cancer cells to express suicide
genes [29, 30] or apoptosis-inducing ligands [32] to transfer death signals to neighboring
non-engineered tumour cells, and engineering cancer cells to express therapeutic agents
that influence the tumour microenvironment [31], specifically angiogenesis. In this work,
we exploit the innate self-homing properties of CTCs to investigate their potential as an
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efficient diagnostic probe and drug delivery vehicle for self-targeted therapy of primary
and metastatic tumours. In our model, the primary tumour had a week to grow and
spontaneously metastasize prior to the injection of experimental CTCs and thus, we assume
it is the experimental CTCs homing to those pre-established sites and not the alternative.
Our imaging data from early time points supports this theory such that some animals
displayed spontaneous metastases prior to the injection of CTCs. Furthermore, our
transwell migration assay data shows that conditioned media from our primary 4T1 cells,
causes increased migration compared to media from our experimental CTC 4T1BR5 cell
line. Previous work using the MDA-MB-231 breast cancer model showed that the
cytokines IL-6 and IL-8 produced by the primary tumour acted as chemoattractants to
efficiently recruit CTCs25. Future work will look to investigate whether the production of
these cytokines is enhanced in 4T1 conditioned media and whether they may contribute to
the self-homing efficiency seen in this model.

Based on our initial imaging results, we engineered our experimental CTCs to express a
suicide gene and used noninvasive imaging to monitor the effects of self-targeted therapy
in contralateral, intratumoural, and metastatic models. In a prodrug converting enzyme
suicide gene therapy system, cancer cells are transfected with a gene that can express an
enzyme with the ability to convert a nontoxic prodrug into an active chemotherapeutic [37].
By incorporating a suicide switch, we can visualize the killing of engineered therapeutic
cancer cells as well as a bystander effect whereby adjacent non-engineered cancer cells are
killed. While there are numerous enzyme/prodrug systems available, we chose to use the
CD:UPRT fusion gene, due to the ability of 5’FU (the active form) to interrogate
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neighbouring cells independently of gap junctions, as well as readily diffuse the blood brain
barrier [34-36]. As a result, the CD/5’FC system has shown to have a more potent bystander
effect than the commonly used HSV-TK/GCV system [57-60]. Furthermore, in comparison
to the traditional CD/5’FC system, we used the CD:UPRT fusion gene, as UPRT can
further convert 5’FU into 5’FUMP, which has shown to have significantly enhanced cancer
killing efficiency in prostate, ovarian and breast cancer subtypes [61, 62]. In the current
study, we were able to visualize therapeutic CTCs that had successfully migrated from the
original to the contralateral MFP but did not observe a significant therapeutic effect.
However, we did observe a decrease in tumour burden when our therapeutic cells were
administered intratumourally (3x105 cells). These findings suggest the ratio of therapeutic
cells to cancer cells may be crucial in generating a significant therapeutic effect in vivo. By
using dual BLI, we also show effective homing and treatment of primary tumours when
therapeutic CTCs were administered systemically and as a result, demonstrate extended
survival in mice treated with 5’FC. Our preliminary data suggests systemically
administered CTCs may also be capable of homing to and treating disseminated breast
cancer metastases. Future work will look to validate these findings in additional mouse
cohorts.

While our findings suggest CTCs have potential as highly-efficient carriers of therapeutic
cargo to primary and metastatic tumour sites, our approach has some limitations to
consider. Most importantly, while CD:UPRT expression was able to kill off many of the
engineered 4T1BR5 cells, some of these cells were capable of avoiding cell death and
generated new tumours. Additionally, while we demonstrate the ability to kill off
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neighbouring non-engineered cancer cells through a bystander effect, some mice show
residual spontaneous metastases following treatment. Future work will explore
incorporating more than one therapeutic gene into the engineered cells. For example, a
CD/HSV-TK system, would allow the administration of two different pro-drugs, creating
a higher likelihood of targeting and treating engineered CTCs while possibly also
enhancing the bystander effect. Additionally, timing of CTC self-homing to pre-established
tumours should be further explored. Our data suggests that three days may not be the
optimal window for systemically administered CTCs to efficiently home to established
metastases. If we administer the pro-drug too early, we may lose some of our therapeutic
CTCs to self-induced toxicity prior to receiving any therapeutic effects on neighbouring
non-engineered cancer cells. Furthermore, a larger window would allow time for
therapeutic cells to proliferate and expand the therapeutic population once they have
reached their tumour target.

In conclusion, our work provides evidence that CTCs are a novel theranostic vector
platform for the visualization and treatment of pre-established tumour sites throughout the
body. Overall, while further refinement is needed, this unorthodox strategy may have
tremendous long term translational potential as a highly effective theranostic platform,
specifically in patient populations presenting with metastatic disease at initial diagnosis,
and those at high risk of cancer recurrence or metastatic relapse.
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4.4

Materials and methods

4.4.1 Cell Engineering
The 4T1BR5 cells were a kind gift from Dr. Patricia Steeg’s lab and engineered to stably
co-express red-shifted Luciola italica luciferase (FLuc) and green fluorescent protein
(GFP) using a commercial lentiviral vector (RediFect Red-FLuc-GFP; PerkinElmer, USA).
Cells were transduced and FACS sorted based on GFP expression using a FACSAria III
flow cytometric cell sorter (BD Biosciences). The parental 4T1 cells were also received
from Dr. Patricia Steeg’s lab and engineered to stably co-express Renilla luciferase-8
(RLuc) and ZsGreen (ZsG) using a virus made in house. Cells were transduced and sorted
based on ZsG expression using FACS. The resultant 4T1BR5-FLuc/GFP (4T1BR5-Fluc)
and 4T1-RLuc/ZsG (4T1-Rluc) cells were maintained in DMEM containing 10% FBS and
1% antibiotics, at 37°C and 5% CO2. The 4T1BR5-FLuc and 4T1-RLuc cells were then
engineered a second time to stably express cytosine deaminase-uracil phosphoribosyl
transferase (CD-UPRT) and tdTomato (tdT). Both cell lines were transduced and FACS
sorted based on tdT expression. Cells were washed three times with Hanks balanced salt
solution (HBSS) and collected for in vitro evaluation or injection into animals.

4.4.2 In Vitro Studies
Cell line characterization
All in vitro results are from three independent experiments with three replicates of each
condition. To evaluate the relationship between cell number and BLI signal, 1x104, 5x104,
1x105, 1.5x105, and 5x105 4T1BR5-FLuc or 4T1-RLuc cells were seeded in each well of
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24-well plates. We acquired fluorescent images of each plate. We then added 10 L of Dluciferin (30 mg/mL; Syd Labs, Inc., MA, USA) or 10 L of h-Coelenterazine (150g/mL;
NanoLight Technology, Prolume, AZ, USA) to the growth medium in each well and BLI
images were collected for up to 35 minutes. All images were acquired using a hybrid
optical/X-ray scanner (IVIS Lumina XRMS In Vivo Imaging System, PerkinElmer).
Signal was measured with region-of-interest (ROI) analysis using LivingImage Software
(Perkin Elmer). An ROI was drawn around each well to measure the radiant efficiency
(p/s/cm2/sr/uW/cm2) for fluorescence images and average radiance (p/s/mm2/sr) for
bioluminescence images. The mean signal across replicates was determined for each
independent experiment.

Cross reactivity
To assess in vitro cross reactivity, we seeded two identical 24-well plates with 1 x 105 4T1RLuc, 4T1BR5-Fluc, 4T1 naïve cells, and equivalent volume of media. We added 10uL of
d-Luciferin to each well in plate 1 and 10uL of h-Coelenterazine to each well in plate 2.
Images were acquired for up to 35 minutes and an ROI was drawn around each well to
measure the average radiance (p/s/mm2/sr). The mean signal across replicates was
determined for each independent experiment.

Transwell Migration Assay
A FluoroBlok™ Multiwell Insert System was used with an 8um porous polyethylene
terephthalate membrane (Corning, Corning NY, USA). We seeded 5x104 cells (4T1-RLuc
or 4T1BR5-Fluc) in 75cm2 flasks. At 48 hours post seeding, 650uL of new or conditioned
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DMEM was collected and used for the bottom chamber of the transwell plate. We then
seeded 2.5x104 cells (4T1-RLuc or 4T1BR5-Fluc) in the upper chamber of the transwell
insert in 100ul of new DMEM. After 24 hours, the membranes were fixed in ethanol for 5
minutes, washed with PBS, and stained with Hoechst 33342 (10ug/ml in water) for 5
minutes. Membranes were cut out with a scalpel and mounted in 90% glycerol onto slides.
Three random images were taken of the lower side of each membrane using an Invitrogen
EVOS FL Auto Cell Imaging System and the mean fluorescence signal was calculated.

CD:UPRT Functionality Testing
To assess the functionality of the CD-UPRT gene in vitro, Vybrant MTT assays were used.
2x104 4T1-RLuc or 4T1-CD cells were seeded in each well of 96-well plates and incubated
in either the desired concentration of 5’FC (diluted in DMEM) or incubated in DMEM
alone. Ten microliters of MTT solution was added to each well and absorbance at 450nm
was measured using a microplate spectrophotometer (Fluoroskan Ascent FL,
ThermoLabSystems) at 24, 48, 72 and 96 hours. This experiment was repeated for
4T1BR5-FLuc and 4T1BR5-FLuc/CD cells.

4.4.3 In Vivo Studies
Animals were cared for in accordance with the standards of the Canadian Council on
Animal Care, and under an approved protocol of the University of Western Ontario’s
Council on Animal Care (2015-0558). Six to eight-week-old female nu/nu mice were
obtained from Charles River Laboratories (Willington, MA, USA).
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Contralateral tumour model
Mice received a lower right mammary fat pad (MFP) injection of 300,000 4T1-Rluc or
4T1-CD cells and a lower left MFP injection of 300,000 4T1BR5-Fluc cells on day 0
(Figure 4.1A; n=5). RLuc BLI was performed on days 0 and 7 and FLuc BLI performed
on days 1 and 8. Additional BLI was performed for experiments with CD expressing cells
on days 15 (RLuc) and 16 (FLuc). For experiments with CD expressing cells, mice
receiving 4T1-Rluc and 4T1-CD cells both received intraperitoneal injections of 5’FC
(250mg/kg/day) on days 7 to 14 (Figure 4.3A; n=8).

Intratumoural model
Mice received a lower right mammary fat pad (MFP) injection of 300,000 4T1BR5-Fluc
cells on day 0 and an intratumoural injection of 300,000 4T1-Rluc or 4T1-CD cells on day
7 (Figure 4.4A; n=8). FLuc BLI was performed on days 0, 4, 8 and 16 and RLuc BLI
performed on days 7 and 15. Mice receiving 4T1BR5-Fluc and 4T1BR5-CD cells both
received intraperitoneal injections of 5’FC (250mg/kg/day) on days 8 to 16.

Metastatic tumour model
Mice received a lower right MFP injection of 300,000 4T1-Rluc cells. MFP tumours grew
for seven days prior to all mice receiving an intracardiac injection of 2x104 4T1BR5-FLuc
or 4T1BR5-CD cells in 0.1mL of HBSS (Figure 4.5A; n=5). Injections were performed
under image guidance using a Vevo 2100 ultrasound system (VisualSonics Inc.). RLuc
BLI was performed on days 0, 6, 13 and 19. FLuc BLI was performed on days 7, 14 and
20. For experiments with CD expressing cells, mice receiving 4T1BR5-FLuc and 4T1BR5-
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CD cells both received intraperitoneal injections of 5’FC (250mg/kg/day) on days 10 to 20
(Figure 4.6A; n=12).

BLI Procedure
BLI was performed using a hybrid optical/X-ray scanner (IVIS Lumina XRMS In Vivo
Imaging System, PerkinElmer). Mice were anesthetized with isoﬂuorane (2% in 100%
oxygen) using a nose cone attached to an activated carbon charcoal filter for passive
scavenging. For RLuc BLI, anesthetized mice received a 20 L intravenous injection of hCoelenterazine (150g/mL) and BLI images were captured for up to 30 minutes. For FLuc
BLI, anesthetized mice received a 100 L intraperitoneal injection of d-Luciferin (30
mg/mL) and BLI images were captured for up to 35 minutes.

Image Analysis
BLI signal was measured with region-of-interest (ROI) analysis using LivingImage
Software (Perkin Elmer). ROIs were drawn throughout the mouse body of RLuc and FLuc
image sets for each mouse.

Histology
At endpoint, mice were sacrificed by isoflurane overdose and perfused with 4%
paraformaldehyde via the left ventricle. Tissues were removed and cryopreserved in
ascending concentrations of sucrose (10, 20, and 30% w/v) for 24 hours each, then
immersed in optimal cutting temperature (OCT) compound, and frozen using liquid
nitrogen. Contiguous 10-m frozen sections were collected and select sections were stained
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with hematoxylin and eosin (H&E), DAPI, Anti-GFP, Anti-Rluc. Stained sections were
imaged using an Invitrogen EVOS FL Auto Cell Imaging System.
Statistics
All statistics were calculated using GraphPad Prism 7 Software. Data were expressed as
mean ± SEM for in vitro and in vivo studies and analyzed by Student’s t test when
comparing two groups. Survival times of mouse groups were analyzed using a log-rank
test. Differences were considered statistically significant at *p < 0.05, **p < 0.01, ***p <
0.001, and ****p < 0.0001.
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Chapter 5

5

Summary and Future Work

In this thesis, we present the first study to use both iron-based cellular MRI and BLI to
longitudinally track cancer metastasis in vivo. Further, we present the first application of
this imaging model to study concomitant tumour enhancement in an immune competent
mouse model of breast cancer metastasis. This is the first application of dual-luciferase
BLI to monitor the long-term fate of two different cancer populations in the same animal
and the first study to use molecular-genetic imaging to visualize whole body tumour selfhoming and effective self-targeted treatment of disseminated metastases.

5.1

Discussion and Conclusions

Tumour self-homing and CTR/CTE are potential mechanisms contributing to cancer
metastasis whereby an existing primary tumour can influence the growth of secondary
tumours at distant sites. The majority of studies have relied on endpoint histology to study
these mechanisms. This thesis employed numerous imaging technologies to noninvasively
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study these biological processes and the impact they may have on the progression of breast
cancer metastasis.

5.1.1 Chapter 2- A multimodality imaging model to track viable
breast cancer cells from single arrest to metastasis in the
mouse brain

In Chapter 2, we combined iron-based cellular MRI with longitudinal BLI to track the fate
of iron-labeled, luciferase expressing brain trophic breast cancer cells in nude mice. This
is the first study demonstrating these complementary technologies can be used together to
get a more holistic view of cancer cell fate in a model of experimental metastasis. In this
work, BLI allowed for repetitive, non-invasive, whole body imaging and MRI based
measurements of single cell arrest and tumour burden were used to validate BLI
measurements. The main findings were:

1. The number of iron labeled cells that arrested throughout the brain on day 0
correlated with BLI measurements of cell viability
2. The decrease in MR void number from day 0 to day 8 correlated with changes in
BLI signal
3. Total brain tumour burden measured with MRI correlated with BLI measurements
of cell viability at endpoint

These findings demonstrate the value in using both technologies to noninvasively monitor
the different stages of the metastatic cascade in vivo. The correlation seen between
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modalities on the day of cell injection suggests that the majority of iron labeled cells that
arrested in the brain are viable. The correlation seen between modalities at endpoint
suggests that the majority of tumour burden visualized with MRI is viable tumour tissue.
Our goal for the following experiment was to investigate the impact of a primary breast
tumour on metastatic growth; thus, we chose to continue with this imaging model to acquire
measurements of cell arrest, tumour burden and cellular viability over time. We predict this
novel multimodality imaging framework will be broadly applicable to other experimental
models of cancer metastasis and useful for evaluating the efficacy of emerging anti-cancer
drugs at different stages of the metastatic cascade.

5.1.2 Chapter 3- Multimodality cellular and molecular imaging
of concomitant tumour enhancement in a syngeneic mouse
model of breast cancer metastasis
In Chapter 3, we successfully applied our multimodality imaging model to study the impact
of a primary 4T1 breast tumour on the growth of 4T1BR5 derived metastases. Previous
literature suggested the size of the primary tumour may influence whether CTR or CTE
occurs [1]; thus, we investigated the impact of both a small and large primary tumour.
While our MR analysis indicated a strong CTE effect regardless of primary tumour size,
our BLI measurements suggested a significant effect on metastasis in mice with large
primary tumours only. The main findings were:

1. The initial arrest and clearance of 4T1BR5 cells in the brain was not significantly
different between mice that had primary tumours and control mice.
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2. Mice bearing small primary tumours had significantly more MR detectable brain
tumour burden at endpoint compared to mice without primary tumours; however,
BLI signal was not significantly different between groups.
3. Mice bearing large primary tumours had significantly more MR detectable brain
tumour burden and BLI signal at endpoint compared to mice without primary
tumours.

These findings further validate the importance of using more than one technology to
evaluate tumour burden in models of metastasis. While we demonstrate strong agreement
between these modalities in our previous study, others have shown that measurements of
tumor size (MRI) and tumor viability (BLI) do not always correlate [2]. With MRI, we are
measuring tumour volume which can include areas of edema, immune cells etc., whereas
BLI is a direct measure of viable engineered cells. Thus, acquiring measurements from
both MRI and BLI can offer valuable insight into the disease state. In this study, by using
in vivo BLI and MRI we could determine differences in endpoint tumour burden were not
related to differences in the initial arrest or clearance of viable cells in the brain, which
suggests that the presence of a primary tumour can increase the proliferative growth of
brain metastases in this syngeneic 4T1 mouse model.

5.1.3 Chapter 4- Engineering self-homing circulating tumour
cells as novel cancer theranostics
In chapter 4, we employed dual-luciferase BLI to evaluate the efficiency of experimental
CTCs to home to disseminated metastases throughout the mouse body. Our imaging data
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supported extremely efficient self-homing of systemically administered CTCs to
disseminated metastases. Based on these results, we next engineered our CTCs to express
a suicide gene to investigate their potential as drug delivery vehicles for self-targeted
therapy of primary and metastatic tumours. The main findings of this study were:

1. Experimental CTCs home to disseminated spontaneous metastases.
2. Systemically administered therapeutic CTCs can effectively home to and treat preexisting primary and metastatic tumours.
3. Dual-luciferase BLI allowed for sensitive visualization of CTC arrest, homing
efficiency, treatment efficacy and long-term fate.

The application of dual-luciferase BLI allowed for sensitive tracking of both cell
populations: metastatic breast cancer cells as well as engineered therapeutic cancer cells.
By incorporating a suicide switch, we show efficient killing of engineered therapeutic
cancer cells as well as a strong bystander effect whereby adjacent non-engineered cancer
cells are killed. Together our findings suggest CTCs should continue to be investigated as
highly-efficient carriers of therapeutic cargo to metastatic tumour sites.

5.2

Limitations

5.2.1 The use of cell lines
The results presented in this thesis are based on observations of preclinical mouse models
of breast cancer metastasis. We employed three commonly used authenticated cell lines,
the murine 4T1/4T1BR5 model and the human derived JIMT1BR model. The use of cell

171

lines in preclinical studies provides many advantages. Cell lines are relatively easy and
inexpensive to maintain. Furthermore, the specific models that were used in this thesis are
quite aggressive, providing a reasonable timeline for longitudinal imaging studies.
However, previous studies have shown that cell lines may not accurately represent the
heterogeneity of tumours that is seen in the clinic [3]. As a result, preclinical findings based
on cell lines do not always translate accordingly. This limitation can be addressed by
implementing patient derived xenograft (PDX) models for preclinical cancer studies. This
involves implanting a tumour fragment or suspension from a patient directly into an
immune compromised animal and continued passaging of any resultant tumours in
additional mice cohorts [4]. In recent years, it has been shown that PDX models have
similar tumour characteristics to those observed in the clinic and as a result, have more
predictive value when translating to patient studies [5,6]. While our group is transitioning
towards the use of PDX models, the aggressive cancer cell lines used in this thesis provided
models of consistent and timely breast cancer brain metastasis that can take months to
generate with PDX models, if at all in the majority of mice. In addition, the ease of
expansion and stability of these cell lines in culture allowed us to genetically engineer them
to express our imaging reporter genes with high efficiency. Moving forward, we will use
the imaging framework and experimental techniques developed in this thesis to study
metastasis in PDX models of breast cancer.

5.2.2 Preclinical imaging techniques
The imaging technologies presented in this thesis are extremely valuable tools for tracking
cancer populations in preclinical animal models. Iron-based cellular MRI enables single
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cell detection throughout the brain providing measurements of cell arrest, cell clearance,
and cell dormancy [7,8]. BLI enables sensitive detection of whole-body metastatic burden
and provides longitudinal measurements of cancer cell viability [9,10]. However, these cell
tracking technologies are limited to preclinical use since they rely on the cancer cells being
labeled in culture. We chose to use these modalities to visualize very early stages of the
metastatic cascade that are not possible to study using clinically relevant modalities. In the
future, we could use conventional MR and/or PET imaging to acquire both anatomical and
functional tumour measurements that would be feasible to obtain in a clinical setting.

5.2.3 Genetically-engineered cells
In this thesis, we employ lentiviral transduction methods to engineer cancer cells to stably
express various imaging reporter genes. While lentiviruses are commonly used due to their
high transduction efficiency, they have some concerns regarding whether the labeling can
change the biology of the engineered cells. Most lentiviral systems that are currently in use
are derived from the human immunodeficiency viruses (HIV) and lentiviral cargo
integrates randomly into the genome upon infection to permit stable expression in both
dividing and non-dividing cell populations [11]. Random integration can cause unwanted
detrimental effects such as transgene silencing, altered cell behavior, or insertional
activation of oncogenes [12-15]. To overcome this, our lab is currently developing
clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPRassociated protein 9 (Cas9) tools to allow for precise editing of cells at the adeno-associated
virus site 1 (AAVS1) safe harbour. Our group has shown successful AAVS1 integration of
large gene constructs necessary for molecular-genetic imaging using the CRISPR/Cas9
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system [16]. Future work is focused on improving the efficiency of this first system, which
will allow us to use it reporter gene-based for cell tracking studies the lack the issues
associated with random integration.

5.3

Future Work

This thesis includes some of the first studies using longitudinal imaging to study the
mechanisms contributing to breast cancer metastasis. Future work will be focused on
translational studies that bridge the gap between our initial findings presented here and
future clinical studies. First, we will implement PDX models of breast cancer to better
understand clinical cases of CTR versus CTE. In addition, future work will focus on
developing more clinically relevant imaging models to visualize CTC self-homing in vivo.

5.3.1 Implementing PDX models to study CTR/CTE
The clinical evidence of CTR and CTE remains lacking due to the fact that investigation
depends on the presence of an existing primary tumour. While there have been reported
cases of both CTR and CTE [17-22], it is not clear what stratifies patients into experiencing
one or the other. With the use of cell lines, we have previously demonstrated CTR in an
immune deficient mouse model as well as CTE in an immune competent mouse model in
the current work [23]. Others have also shown that both CTR and CTE can occur within
the same animals depending on the ratio of the size of primary tumour to secondary tumour
[1]. By implementing PDX models to study CTR/CTE, we may be able to better represent
the tumour heterogeneity that is evident in the clinic to more accurately identify breast
cancer patients that would benefit from tumour resection or alternative therapy.
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5.3.2 Visualizing CTC tumour self-homing with a clinically relevant imaging modality
In chapter 4, we employed dual-luciferase BLI to sensitively monitor CTC self-homing
efficiency to primary and metastatic tumour sites. In future studies, we want to investigate
whether CTC self-homing can be visualized with other technologies we use in our lab such
as iron-based cellular MR and Fluorine-19 MR. Iron-based cellular MRI may enable
detection of single iron labeled self-homing CTCs, while Fluorine-19 MR would provide
a quantifiable technique to estimate the number of CTCs that home to a targeted tumour
site.

We also plan to investigate the use of a human derived MR reporter gene to track the
engineered CTCs in our mouse models. Our group has recently shown that the organic
anion transporting polypeptide 1 (OATP1), a protein that is naturally expressed in the
human liver, can be encoded into cancer cells for enhanced uptake of the gadolinium agent
Gd-EOB-DTPA, and thus, improved detection by MR [24].

This reporter has high

translational potential as it will avoid potential immune reactions in patients that may be
caused by other reporter genes such as virally-derived HSV-TK, and Gd-EOB-DTPA is
clinically used.
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Appendices
Appendix A: Supplementary Figures

Supplementary Figure 3.1: A/B) 4T1-BR5 cells were transduced and sorted to stably
co-express Red-FLuc/GFP using a commercial lentiviral vector (Scale bars = 100
microns). C) The resultant 4T1BR5-Red-FLuc/GFP cells were efficiently labeled with
> 90% of cells labeled with MPIO prior to intracardiac injection (Scale bar = 200
microns). D) No significant difference in BLI signal was detected in 4T1BR5-RedFLuc/GFP cells that were labeled with MPIO and cells that were not labeled. Data is
presented as mean +/- SD.
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Supplementary Figure 3.2: A significant positive correlation was found between the
number of 4T1BR5-Red-FLuc/GFP cells and BLI signal (A). There was not a
significant difference in cellular proliferation detected between naïve 4T1-BR5 and
4T1BR5-Red-FLuc/GFP cells (B). 4T1-BR5-Red-Fluc/GFP cells showed no
significant change in Red-Fluc expression over multiple passages in vitro (C).
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Supplementary Figure 3.3: A) Lung metastases (circled in yellow) were detectable at
day 14 with whole body MRI in mice with a large MFP primary tumor, but C) not
control mice. B) BLI signal was also detected in the lung region of large MFP mice on
day 14, but D) not control mice.
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Supplementary Figure 3.4: A representative in vivo MR image of the brain (A) and
corresponding ex vivo BLI (B); in vivo (C) and ex vivo (D) whole body BLI were also
matched presenting signal in the abdominal region.
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Supplementary Figure 3.5: A representative MR slice (A/D) corresponded well with
GFP positive cells (B/E) and H&E staining (C/F) confirming that MR-detectable
metastases contain 4T1BR5-Red-FLuc/GFP cells. Scale bars = 500 microns.

183

Supplementary Figure 4.1: 4T1 cells were transduced with a lentiviral vector
encoding both RLuc and ZsGreen and sorted to obtain 4T1-RLuc cells (Suppl. Fig.
1A). No significant change in ZsGreen expression over multiple passages was seen
(B). There was a significant positive correlation shown between the number of 4T1RLuc cells and RLuc/ZsGreen signal (C). 4T1BR5-FLuc cells incubated with Dluciferin demonstrated significantly higher BLI signal than 4T1-RLuc cells, 4T1
parental cells, or equivalent volume of media, and 4T1-RLuc cells did not produce
signal significantly different than 4T1 parental cells or media alone (D). Similarly,
after the addition of h-coelenterazine, 4T1-RLuc cells had significantly higher signal
than 4T1BR5-FLuc cells, 4T1 parental cells, or equivalent volume of media and
4T1BR5-FLuc cells did not produce signal significantly different than 4T1 parental
cells or media alone (E). A significant increase in cell migration was seen for 4T1BR5
cells when conditioned media from 4T1 cells was used compared to conditioned media
from 4T1BR5 cells or unconditioned media (F). A significant increase in cell
migration was also seen for 4T1 cells when conditioned media from 4T1 cells was used
compared to unconditioned media (F).
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Supplementary Figure 4.2: In vivo cross reactivity: 4T1-RLuc cells were implanted
into the right MFP of nude mice (n=5) and 4T1BR5-FLuc cells were implanted into
the contralateral (left) MFP (A). This allowed us to validate the lack of substrate
cross-reactivity in vivo at early time points after cell injection. On Day 0, 4T1-RLuc
cells only showed signal after administration with h-coelenterazine and signal in the
right MFP was significantly higher than the left (B). Similarly, on Day 1, 4T1BR5FLuc cells only showed signal after administration of d-Luciferin and signal in the
left MFP was significantly higher than in the right MFP (C).
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Supplementary Figure 4.3: 4T1BR5-FLuc cells were transduced with a lentiviral
vector co-expressing the therapeutic prodrug converting fusion enzyme cytosine
deaminase-uracil phosphoribosyltransferase (CD:UPRT) and tdTomato (tdT), and
sorted via tdT to obtain 4T1BR5-FLuc/CD cells (A). After 96 hours of incubation with
5’FC (5mM), CD expressing cells showed significantly less survival than cells without
drug as well as significantly less survival than 4T1BR5-FLuc with or without drug
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(B). At all doses, CD expressing cells show significantly less survival than cells without
drug (C).
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Supplementary Figure 4.4: At endpoint, the number of metastases that were
composed of both 4T1-RLuc and 4T1BR5-FLuc cells was significantly higher than
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the number of metastases that were either 4T1-RLuc-positive only or 4T1BR5-FLucpositive only (A). The presence of both 4T1-RLuc and 4T1BR5-FLuc cells in
numerous metastases was confirmed histologically (B). Using dual-BLI, we detected
some whole-body metastases that had stronger FLuc signal than RLuc signal as well
as metastases that had stronger RLuc signal than FLuc signal (X-axis values= mouse
number followed by tumour number) (C).
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